

2016

THE MASTER OF PHARMACY (M. PHARM.) COURSE REGULATION 2014

(BASED ON NOTIFICATION IN THE GAZETTE OF INDIA No. 362, DATED DECEMBER 11, 2014)

SCHEME AND SYLLABUS



PHARMACY COUNCIL OF INDIA

Combined Council's Building, Kotla Road,
Aiwan-E-Ghalib Marg, New Delhi-110 002.
Website : www.pci.nic.

COURSE STRUCTURE AND SYLLABUS
For
M. PHARM

MPH R 18 Regulations

(Applicable for batches admitted from 2018-2019)



JAWAHARLAL NEHRU TECHNOLOGICAL
UNIVERSITY: KAKINADA
KAKINADA - 533 003, Andhra Pradesh, India

Table of Contents

| S.No. | Content | Page.No. |
|-------|---|----------|
| | Regulations | 05 |
| 1. | Short Title and Commencement | 05 |
| 2. | Minimum qualification for admission | 05 |
| 3. | Duration of the program | 05 |
| 4. | Medium of instruction and examinations | 05 |
| 5. | Working days in each semester | 05 |
| 6. | Attendance and progress | 05 |
| 7. | Program/Course credit structure | 05 |
| 8. | Academic work | 06 |
| 9. | Course of study | 06 |
| 10. | Program Committee | 18 |
| 11. | Examinations/Assessments | 18 |
| 12. | Promotion and award of grades | 30 |
| 13. | Carry forward of marks | 30 |
| 14. | Improvement of internal assessment | 30 |
| 15. | Reexamination of end semester examinations | 30 |
| 16. | Allowed to keep terms (ATKT) | 31 |
| 17. | Grading of performances | 31 |
| 18. | The Semester grade point average (SGPA) | 31 |
| 19. | Cumulative Grade Point Average (CGPA) | 32 |
| 20. | Declaration of class | 32 |
| 21. | Project work | 32 |
| 22. | Award of Ranks | 33 |
| 23. | Award of degree | 33 |
| 24. | Duration for completion of the program of study | 33 |
| 25. | Revaluation I Retotaling of answer papers | 33 |
| 26. | Re-admission after break of study | 33 |
| 27. | Pharmaceutics (MPH) | 34 |
| 28. | Industrial Pharmacy (MIP) | 51 |
| 29. | Pharmaceutical Chemistry (MPC) | 66 |
| 30. | Pharmaceutical Analysis (MPA) | 84 |
| 31. | Pharmaceutical Quality Assurance (MQA) | 102 |
| 32. | Pharmaceutical Regulatory Affairs (MRA) | 120 |
| 33. | Pharmaceutical Biotechnology (MPB) | 140 |
| 34. | Pharmacy Practice (MPP) | 158 |
| 35. | Pharmacology (MPL) | 176 |
| 36. | Pharmacognosy (MPG) | 195 |
| 37. | Research Methodology & Biostatistics (MRM) | 213 |



भारत का राजपत्र The Gazette of India

असाधारण

EXTRAORDINARY

भाग III—खण्ड 4

PART III—Section 4

प्रधिकार से प्रकाशित

PUBLISHED BY AUTHORITY

सं. ३६२]

नई दिल्ली, बुधवार, दिसम्बर ११, २०१४/अग्रहायण २०, १९३६

No. 362]

NEW DELHI, THURSDAY, DECEMBER 11, 2014/AGRAHAYANA 20, 1936

PHARMACY COUNCIL OF INDIA NOTIFICATION

New Delhi, the 10th December, 2014

The Master of Pharmacy (M.Pharm) Course Regulations, 2014

No. 14-136/ 2014-PCI.—In exercise of the powers conferred by Sections 10 and 18 of the Pharmacy Act, 1948 (8 of 1948), the Pharmacy Council of India, with the approval of the Central Government hereby makes the following regulations: namely—

CHAPTER –I: REGULATIONS

1. Short Title and Commencement

These regulations shall be called as “The Revised Regulations for the Master of Pharmacy (M. Pharm.) Degree Program - Credit Based Semester System (CBSS) of the Pharmacy Council of India, New Delhi”. They shall come into effect from the Academic Year 2016-17. The regulations framed are subject to modifications from time to time by the authorities of the university.

2. Minimum qualification for admission

A Pass in the following examinations

a) B. Pharm Degree examination of an Indian university established by law in India from an institution approved by Pharmacy Council of India and has scored not less than 55 % of the maximum marks (aggregate of 4 years of B.Pharm.)

b) Every student, selected for admission to post graduate pharmacy program in any PCI approved institution should have obtained registration with the State Pharmacy Council or should obtain the same within one month from the date of his/her admission, failing which the admission of the candidate shall be cancelled.

Note: It is mandatory to submit a migration certificate obtained from the respective university where the candidate had passed his/her qualifying degree (B.Pharm.)

3. Duration of the program

The program of study for M.Pharm. shall extend over a period of four semesters (two academic years). The curricula and syllabi for the program shall be prescribed from time to time by Pharmacy Council of India, New Delhi.

4. Medium of instruction and examinations

Medium of instruction and examination shall be in English.

5. Working days in each semester

Each semester shall consist of not less than 100 working days. The odd semesters shall be conducted from the month of June/July to November/December and the even semesters shall be conducted from the month of December/January to May/June in every calendar year.

6. Attendance and progress

A candidate is required to put in at least 80% attendance in individual courses considering theory and practical separately. The candidate shall complete the prescribed course satisfactorily to be eligible to appear for the respective examinations.

7. Program/Course credit structure

As per the philosophy of Credit Based Semester System, certain quantum of academic work viz. theory classes, practical classes, seminars, assignments, etc. are measured in terms of credits. On satisfactory completion of the courses, a candidate earns credits. The amount of credit associated with a course is dependent upon the number of hours of instruction per week in that course. Similarly the credit associated with any of the other academic, co/extra- curricular activities is dependent upon the quantum of work expected to be put in for each of these activities per week/per activity.

7.1. Credit assignment

7.1.1. Theory and Laboratory courses

Courses are broadly classified as Theory and Practical. Theory courses consist of lecture (L) and Practical (P) courses consist of hours spent in the laboratory. Credits (C) for a course is dependent on the number of hours of instruction per week in that course, and is obtained by using a multiplier of one (1) for lecture and a multiplier of half (1/2) for practical (laboratory) hours. Thus, for example, a theory course having four lectures per week throughout the semester carries a credit of 4. Similarly, a practical having four laboratory hours per week throughout semester carries a credit of 2.

The contact hours of seminars, assignments and research work shall be treated as that of practical courses for the purpose of calculating credits. i.e., the contact hours shall be multiplied by 1/2. Similarly, the contact hours of journal club, research work presentations and discussions with the supervisor shall be considered as theory course and multiplied by 1.

7.2. Minimum credit requirements

The minimum credit points required for the award of M. Pharm. degree is 95. However based on the credit points earned by the students under the head of co-curricular activities, a student shall earn a maximum of 100 credit points. These credits are divided into Theory courses, Practical, Seminars, Assignments, Research work, Discussions with the supervisor, Journal club and Co-Curricular activities over the duration of four semesters. The credits are distributed semester-wise as shown in Table 14. Courses generally progress in sequence, building competencies and their positioning indicates certain academic maturity on the part of the learners. Learners are expected to follow the semester-wise schedule of courses given in the syllabus.

8. Academic work

A regular record of attendance both in Theory, Practical, Seminar, Assignment, Journal club, Discussion with the supervisor, Research work presentation and Dissertation shall be maintained by the department / teaching staff of respective courses.

9. Course of study

The specializations in M.Pharm program is given in Table 1.

Table – 1: List of M.Pharm. Specializations and their Code

| S. No. | Specialization | Code |
|--------|-----------------------------------|------|
| 1. | Pharmaceutics | MPH |
| 2. | Industrial Pharmacy | MIP |
| 3. | Pharmaceutical Chemistry | MPC |
| 4. | Pharmaceutical Analysis | MPA |
| 5. | Pharmaceutical Quality Assurance | MQA |
| 6. | Pharmaceutical Regulatory Affairs | MRA |
| 7. | Pharmaceutical Biotechnology | MPB |
| 8. | Pharmacy Practice | MPP |
| 9. | Pharmacology | MPL |
| 10. | Pharmacognosy | MPG |

The course of study for M.Pharm specializations shall include Semester wise Theory & Practical as given in Table – 2 to 11. The number of hours to be devoted to each theory and practical course in any semester shall not be less than that shown in Table – 2 to 11.

Table – 2: Course of study for M. Pharm. (Pharmaceutics)

| Course Code | Course | Credit Hours | Credit Points | Hrs./wk | Marks |
|--------------------|---|--------------|---------------|-----------|------------|
| Semester I | | | | | |
| MPH101T | Modern Pharmaceutical Analytical Techniques | 4 | 4 | 4 | 100 |
| MPH102T | Drug Delivery System | 4 | 4 | 4 | 100 |
| MPH103T | Modern Pharmaceutics | 4 | 4 | 4 | 100 |
| MPH104T | Regulatory Affair | 4 | 4 | 4 | 100 |
| MPH105PA | Pharmaceutics Practical I | 6 | 3 | 6 | 75 |
| MPH105PB | Pharmaceutical Practical II | 6 | 3 | 6 | 75 |
| - | Seminar/Assignment | 7 | 4 | 7 | 100 |
| Total | | 35 | 26 | 35 | 650 |
| Semester II | | | | | |
| MPH201T | Molecular Pharmaceutics (Nano Tech and Targeted DDS) | 4 | 4 | 4 | 100 |
| MPH202T | Advanced Biopharmaceutics & Pharmacokinetics | 4 | 4 | 4 | 100 |
| MPH203T | Computer Aided Drug Delivery System | 4 | 4 | 4 | 100 |
| MPH204T | Formulation Development of Pharmaceutical and Cosmetic Products | 4 | 4 | 4 | 100 |
| MPH205PA | Pharmaceutics Practical III | 6 | 3 | 6 | 75 |
| MPH205PB | Pharmaceutics Practical IV | 6 | 3 | 6 | 75 |
| - | Seminar/Assignment | 7 | 4 | 7 | 100 |
| Total | | 35 | 26 | 35 | 650 |

Table – 3: Course of study for M. Pharm. (Industrial Pharmacy)

| Course Code | Course | Credit Hours | Credit Points | Hrs./wk | Marks |
|--------------|--|--------------|---------------|-----------|------------|
| Semester I | | | | | |
| MIP101T | Modern Pharmaceutical Analytical Techniques | 4 | 4 | 4 | 100 |
| MIP102T | Pharmaceutical Formulation Development | 4 | 4 | 4 | 100 |
| MIP103T | Novel drug delivery systems | 4 | 4 | 4 | 100 |
| MIP104T | Intellectual Property Rights | 4 | 4 | 4 | 100 |
| MIP105PA | Industrial Pharmacy Practical I | 6 | 3 | 6 | 75 |
| MIP105PB | Industrial Pharmacy Practical II | 6 | 3 | 6 | 75 |
| - | Seminar/Assignment | 7 | 4 | 7 | 100 |
| Total | | 35 | 26 | 35 | 650 |
| Semester II | | | | | |
| MIP201T | Advanced Biopharmaceutics and Pharmacokinetics | 4 | 4 | 4 | 100 |
| MIP202T | Scale up and Technology Transfer | 4 | 4 | 4 | 100 |
| MIP203T | Pharmaceutical Production Technology | 4 | 4 | 4 | 100 |
| MIP204T | Entrepreneurship Management | 4 | 4 | 4 | 100 |
| MIP205PA | Industrial Pharmacy Practical III | 6 | 3 | 6 | 75 |
| MIP205PB | Industrial Pharmacy Practical IV | 6 | 3 | 6 | 75 |
| - | Seminar/Assignment | 7 | 4 | 7 | 100 |
| Total | | 35 | 26 | 35 | 650 |

Table – 4: Course of study for M. Pharm. (Pharmaceutical Chemistry)

| Course Code | Course | Credit Hours | Credit Points | Hrs./wk | Marks |
|-------------|---|--------------|---------------|---------|-------|
| Semester I | | | | | |
| MPC101T | Modern Pharmaceutical Analytical Techniques | 4 | 4 | 4 | 100 |
| MPC1012T | Advanced Organic Chemistry -I | 4 | 4 | 4 | 100 |
| MPC103T | Advanced Medicinal chemistry | 4 | 4 | 4 | 100 |
| MPC104T | Chemistry of Natural Products | 4 | 4 | 4 | 100 |
| MPC105PA | Pharmaceutical Chemistry Practical I | 6 | 3 | 6 | 75 |
| MPC105PB | Pharmaceutical Chemistry Practical II | 6 | 3 | 6 | 75 |
| - | Seminar/Assignment | 7 | 4 | 7 | 100 |
| Total | | 35 | 26 | 35 | 650 |
| Semester II | | | | | |
| MPC201T | Advanced Spectral Analysis | 4 | 4 | 4 | 100 |
| MPC202T | Advanced Organic Chemistry -II | 4 | 4 | 4 | 100 |
| MPC203T | Computer Aided Drug Design | 4 | 4 | 4 | 100 |
| MPC204T | Pharmaceutical Process Chemistry | 4 | 4 | 4 | 100 |
| MPC205PA | Pharmaceutical Chemistry Practical III | 6 | 3 | 6 | 75 |
| MPC105PB | Pharmaceutical Chemistry Practical IV | 6 | 3 | 6 | 75 |
| - | Seminar/Assignment | 7 | 4 | 7 | 100 |
| Total | | 35 | 26 | 35 | 650 |

Table – 5: Course of study for M. Pharm. (Pharmaceutical Analysis)

| Course Code | Course | Credit Hours | Credit Points | Hrs./wk | Marks |
|--------------------|---|--------------|---------------|-----------|------------|
| Semester I | | | | | |
| MPA101T | Modern Pharmaceutical Analytical Techniques | 4 | 4 | 4 | 100 |
| MPA102T | Advanced Pharmaceutical Analysis | 4 | 4 | 4 | 100 |
| MPA103T | Pharmaceutical Validation | 4 | 4 | 4 | 100 |
| MPA104T | Food Analysis | 4 | 4 | 4 | 100 |
| MPA105PA | Pharmaceutical Analysis Practical I | 6 | 3 | 6 | 75 |
| MPA105PB | Pharmaceutical Analysis Practical II | 6 | 3 | 6 | 75 |
| - | Seminar/Assignment | 7 | 4 | 7 | 100 |
| Total | | 35 | 26 | 35 | 650 |
| Semester II | | | | | |
| MPA201T | Advanced Instrumental Analysis | 4 | 4 | 4 | 100 |
| MPA202T | Modern Bio-Analytical Techniques | 4 | 4 | 4 | 100 |
| MPA203T | Quality Control and Quality Assurance | 4 | 4 | 4 | 100 |
| MPA204T | Herbal and Cosmetic Analysis | 4 | 4 | 4 | 100 |
| MPA205PA | Pharmaceutical Analysis Practical III | 6 | 3 | 6 | 75 |
| MPA205PB | Pharmaceutical Analysis Practical IV | 6 | 3 | 6 | 75 |
| - | Seminar/Assignment | 7 | 4 | 7 | 100 |
| Total | | 35 | 26 | 35 | 650 |

Table – 6: Course of study for M. Pharm. (Pharmaceutical Quality Assurance)

| Course Code | Course | Credit Hours | Credit Points | Hrs./wk | Marks |
|--------------------|--|--------------|---------------|-----------|------------|
| Semester I | | | | | |
| MQA101T | Modern Pharmaceutical Analytical Techniques | 4 | 4 | 4 | 100 |
| MQA102T | Quality Management System | 4 | 4 | 4 | 100 |
| MQA103T | Quality Control and Quality Assurance | 4 | 4 | 4 | 100 |
| MQA104T | Product Development and Technology Transfer | 4 | 4 | 4 | 100 |
| MQA105PA | Pharmaceutical Quality Assurance Practical I | 6 | 3 | 6 | 75 |
| MQA105PB | Pharmaceutical Quality Assurance Practical II | 6 | 3 | 6 | 75 |
| - | Seminar/Assignment | 7 | 4 | 7 | 100 |
| Total | | 35 | 26 | 35 | 650 |
| Semester II | | | | | |
| MQA201T | Hazards and Safety Management | 4 | 4 | 4 | 100 |
| MQA202T | Pharmaceutical Validation | 4 | 4 | 4 | 100 |
| MQA203T | Audits and Regulatory Compliance | 4 | 4 | 4 | 100 |
| MQA204T | Pharmaceutical Manufacturing Technology | 4 | 4 | 4 | 100 |
| MQA205PA | Pharmaceutical Quality Assurance Practical III | 6 | 3 | 6 | 75 |
| MQA205PB | Pharmaceutical Quality Assurance Practical IV | 6 | 3 | 6 | 75 |
| - | Seminar/Assignment | 7 | 4 | 7 | 100 |
| Total | | 35 | 26 | 35 | 650 |

Table – 7: Course of study for M. Pharm. (Regulatory Affairs)

| Course Code | Course | Credit Hours | Credit Points | Hrs./wk | Marks |
|--------------------|--|--------------|---------------|-----------|------------|
| Semester I | | | | | |
| MRA101T | Good Regulatory Practices | 4 | 4 | 4 | 100 |
| MRA102T | Documentation and Regulatory Writing | 4 | 4 | 4 | 100 |
| MRA103T | Clinical Research Regulations | 4 | 4 | 4 | 100 |
| MRA104T | Regulations and Legislation for Drugs & Cosmetics, Medical Devices, Biologicals & Herbals, and Food & Nutraceuticals In India and Intellectual Property Rights | 4 | 4 | 4 | 100 |
| MRA105PA | Regulatory Affairs Practical I | 6 | 3 | 6 | 75 |
| MRA105PB | Regulatory Affairs Practical II | 6 | 3 | 6 | 75 |
| | Seminar/Assignment | 7 | 4 | 7 | 100 |
| | Total | 35 | 26 | 35 | 650 |
| Semester II | | | | | |
| MRA201T | Regulatory Aspects of Drugs & Cosmetics | 4 | 4 | 4 | 100 |
| MRA202T | Regulatory Aspects of Herbal & Biologicals | 4 | 4 | 4 | 100 |
| MRA203T | Regulatory Aspects of Medical Devices | 4 | 4 | 4 | 100 |
| MRA204T | Regulatory Aspects of Food & Nutraceuticals | 4 | 4 | 4 | 100 |
| MRA205PA | Regulatory Affairs Practical III | 6 | 3 | 6 | 75 |
| MRA205PB | Regulatory Affairs Practical IV | 6 | 3 | 6 | 75 |
| | Seminar/Assignment | 7 | 4 | 7 | 100 |
| | Total | 35 | 26 | 35 | 650 |

Table – 8: Course of study for M. Pharm. (Pharmaceutical Biotechnology)

| Course Code | Course | Credit Hours | Credit Points | Hrs./wk | Marks |
|--------------------|---|--------------|---------------|-----------|------------|
| Semester I | | | | | |
| MPB101T | Modern Pharmaceutical Analytical Techniques | 4 | 4 | 4 | 100 |
| MPB102T | Microbial And Cellular Biology | 4 | 4 | 4 | 100 |
| MPB103T | Bioprocess Engineering and Technology | 4 | 4 | 4 | 100 |
| MPB104T | Advanced Pharmaceutical Biotechnology | 4 | 4 | 4 | 100 |
| MPB105PA | Pharmaceutical Biotechnology Practical I | 6 | 3 | 6 | 75 |
| MPB105PB | Pharmaceutical Biotechnology Practical II | 6 | 3 | 6 | 75 |
| - | Seminar/Assignment | 7 | 4 | 7 | 100 |
| Total | | 35 | 26 | 35 | 650 |
| Semester II | | | | | |
| MPB201T | Proteins and protein Formulation | 4 | 4 | 4 | 100 |
| MPB202T | Immunotechnology | 4 | 4 | 4 | 100 |
| MPB203T | Bioinformatics and Computer Technology | 4 | 4 | 4 | 100 |
| MPB204T | Biological Evaluation of Drug Therapy | 4 | 4 | 4 | 100 |
| MPB205PA | Pharmaceutical Biotechnology Practical III | 6 | 3 | 6 | 75 |
| MPB205PB | Pharmaceutical Biotechnology Practical IV | 6 | 3 | 6 | 75 |
| - | Seminar/Assignment | 7 | 4 | 7 | 100 |
| Total | | 35 | 26 | 35 | 650 |

Table – 9: Course of study for M. Pharm. (Pharmacy Practice)

| Course Code | Course | Credit Hours | Credit Points | Hrs./wk | Marks |
|--------------------|---|--------------|---------------|-----------|------------|
| Semester I | | | | | |
| MPP101T | Clinical Pharmacy Practice | 4 | 4 | 4 | 100 |
| MPP102T | Pharmacotherapeutics-I | 4 | 4 | 4 | 100 |
| MPP103T | Hospital & Community Pharmacy | 4 | 4 | 4 | 100 |
| MPP104T | Clinical Research | 4 | 4 | 4 | 100 |
| MPP105PA | Pharmacy Practice Practical I | 6 | 3 | 6 | 75 |
| MPP105PB | Pharmacy Practice Practical II | 6 | 3 | 6 | 75 |
| - | Seminar/Assignment | 7 | 4 | 7 | 100 |
| Total | | 35 | 26 | 35 | 650 |
| Semester II | | | | | |
| MPP201T | Principles of Quality Use of Medicines | 4 | 4 | 4 | 100 |
| MPP102T | Pharmacotherapeutics II | 4 | 4 | 4 | 100 |
| MPP203T | Clinical Pharmacokinetics and Therapeutic Drug Monitoring | 4 | 4 | 4 | 100 |
| MPP204T | Pharmacoepidemiology & Pharmacoconomics | 4 | 4 | 4 | 100 |
| MPP205PA | Pharmacy Practice Practical III | 6 | 3 | 6 | 75 |
| MPP205PB | Pharmacy Practice Practical IV | 6 | 3 | 6 | 75 |
| - | Seminar/Assignment | 7 | 4 | 7 | 100 |
| Total | | 35 | 26 | 35 | 650 |

Table – 10: Course of study for (Pharmacology)

| Course Code | Course | Credit Hours | Credit Points | Hrs./wk | Marks |
|--------------------|--|--------------|---------------|-----------|------------|
| Semester I | | | | | |
| MPL101T | Modern Pharmaceutical Analytical Techniques | 4 | 4 | 4 | 100 |
| MPL102T | Advanced Pharmacology-I | 4 | 4 | 4 | 100 |
| MPL103T | Pharmacological and Toxicological Screening Methods-I | 4 | 4 | 4 | 100 |
| MPL104T | Cellular and Molecular Pharmacology | 4 | 4 | 4 | 100 |
| MPL105PA | Pharmacology Practical I | 6 | 3 | 6 | 75 |
| MPL105PB | Pharmacology Practical II | 6 | 3 | 6 | 75 |
| - | Seminar/Assignment | 7 | 4 | 7 | 100 |
| Total | | 35 | 26 | 35 | 650 |
| Semester II | | | | | |
| MPL201T | Advanced Pharmacology II | 4 | 4 | 4 | 100 |
| MPL202T | Pharmacological and Toxicological Screening Methods-II | 4 | 4 | 4 | 100 |
| MPL203T | Principles of Drug Discovery | 4 | 4 | 4 | 100 |
| MPL204T | Experimental Pharmacology practical- II | 4 | 4 | 4 | 100 |
| MPL205PA | Pharmacology Practical III | 6 | 3 | 6 | 75 |
| MPL205PB | Pharmacology Practical IV | 6 | 3 | 6 | 75 |
| - | Seminar/Assignment | 7 | 4 | 7 | 100 |
| Total | | 35 | 26 | 35 | 650 |

Table – 11: Course of study for M. Pharm. (Pharmacognosy)

| Course Code | Course | Credit Hours | Credit Points | Hrs./wk | Marks |
|--------------------|---|--------------|---------------|-----------|------------|
| Semester I | | | | | |
| MPG101T | Modern Pharmaceutical Analytical Techniques | 4 | 4 | 4 | 100 |
| MPG102T | Advanced Pharmacognosy-1 | 4 | 4 | 4 | 100 |
| MPG103T | Phytochemistry | 4 | 4 | 4 | 100 |
| MPG104T | Industrial Pharmacognostical Technology | 4 | 4 | 4 | 100 |
| MPG105PA | Pharmacognosy Practical I | 6 | 3 | 6 | 75 |
| MPG105PB | Pharmacognosy Practical II | 6 | 3 | 6 | 75 |
| - | Seminar/Assignment | 7 | 4 | 7 | 100 |
| Total | | 35 | 26 | 35 | 650 |
| Semester II | | | | | |
| MPG201T | Medicinal Plant biotechnology | 4 | 4 | 4 | 100 |
| MPG102T | Advanced Pharmacognosy-II | 4 | 4 | 4 | 100 |
| MPG203T | Indian system of medicine | 4 | 4 | 4 | 100 |
| MPG204T | Herbal cosmetics | 4 | 4 | 4 | 100 |
| MPG205PA | Pharmacognosy Practical III | 6 | 3 | 6 | 75 |
| MPG205PB | Pharmacognosy Practical IV | 6 | 3 | 6 | 75 |
| - | Seminar/Assignment | 7 | 4 | 7 | 100 |
| Total | | 35 | 26 | 35 | 650 |

Table – 12: Course of study for M. Pharm. III Semester
(Common for All Specializations)

| Course Code | Course | Credit Hours | Credit Points |
|--------------|---|--------------|---------------|
| MRM301T | Research Methodology and Biostatistics* | 4 | 4 |
| - | Journal club | 1 | 1 |
| - | Discussion / Presentation (Proposal Presentation) | 2 | 2 |
| - | Research Work | 28 | 14 |
| Total | | 35 | 21 |

* Non University Exam

Table – 13: Course of study for M. Pharm. IV Semester
(Common for All Specializations)

| Course Code | Course | Credit Hours | Credit Points |
|--------------|-------------------------------|--------------|---------------|
| - | Journal Club | 1 | 1 |
| - | Research Work | 31 | 16 |
| - | Discussion/Final Presentation | 3 | 3 |
| Total | | 35 | 20 |

Table – 14: Semester wise credits distribution

| Semester | Credit Points |
|---|------------------------------------|
| I | 26 |
| II | 26 |
| III | 21 |
| IV | 20 |
| Co-curricular Activities (Attending Conference, Scientific Presentations and Other Scholarly Activities) | Minimum=02 Maximum=07* |
| Total Credit Points | Minimum=95 Maximum=100* |

*Credit Points for Co-curricular Activities

Table – 15: Guidelines for Awarding Credit Points for Co-curricular Activities

| Name of the Activity | Maximum Credit Points Eligible / Activity |
|--|---|
| Participation in National Level Seminar/Conference/Workshop/Symposium/ Training Programs (related to the specialization of the student) | 01 |
| Participation in international Level Seminar/Conference/Workshop/Symposium/ Training Programs (related to the specialization of the student) | 02 |
| Academic Award/Research Award from State Level/National Agencies | 01 |
| Academic Award/Research Award from International Agencies | 02 |
| Research / Review Publication in National Journals (Indexed in Scopus / Web of Science) | 01 |
| Research / Review Publication in International Journals (Indexed in Scopus / Web of Science) | 02 |

Note: International Conference: Held outside India; International Journal: The Editorial Board Outside India

*The credit points assigned for extracurricular and or co-curricular activities shall be given by the Principals of the colleges and the same shall be submitted to the University. The criteria to acquire this credit point shall be defined by the colleges from time to time.

10. Program Committee

The M. Pharm. programme shall have a Programme Committee constituted by the Head of the Institution in consultation with all the Heads of the departments.

The composition of the Programme Committee shall be as follows:

A teacher at the cadre of Professor shall be the Chairperson; One Teacher from each M.Pharm specialization and four student representatives (two from each academic year), nominated by the Head of the institution.

Duties of the Programme Committee:

Periodically reviewing the progress of the classes.

Discussing the problems concerning curriculum, syllabus and the conduct of classes.

Discussing with the course teachers on the nature and scope of assessment for the course and the same shall be announced to the students at the beginning of respective semesters.

1. Communicating its recommendation to the Head of the Institution on academic matters.
2. The Programme Committee shall meet at least twice in a semester preferably at the end of each sessional exam and before the end semester exam.

11. Examinations/Assessments

The schemes for internal assessment and end semester examinations are given from Table–16.

11.1. End semester examinations

The End Semester Examinations for each theory and practical course through semesters I to IV shall be conducted by the respective university except for the subject with asterix symbol (*) for which examinations shall be conducted by the subject experts at college level and the marks/grades shall be submitted to the university.

Tables – 16: Schemes for internal assessments and end semester (Pharmaceutics- MPH)

| Course Code | Course | Internal Assessment | | | | End Semester Exams | | Total Marks |
|--------------------|---|---------------------|-----------------|----------|-------|--------------------|----------|-------------|
| | | Continues Mode | Sessional Exams | | Total | Marks | Duration | |
| | | | Marks | Duration | | | | |
| SEMESTER I | | | | | | | | |
| MPH101T | Modern Pharmaceutical Analytical Techniques | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPH102T | Drug Delivery Systems | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPH103T | Modern Pharmaceutics | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPH104T | Regulatory Affairs | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPH105PA | Pharmaceutics Practical I | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| MPH105PB | Pharmaceutics Practical II | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| - | Seminar/Assignment | - | - | - | - | - | - | 100 |
| Total | | | | | | | | 650 |
| SEMESTER II | | | | | | | | |
| MPH201T | Molecular Pharmaceutics (Nano Tech and Targeted DDS) | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPH202T | Advanced Biopharmaceutics & Pharmacokinetics | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPH203T | Computer Aided Drug Delivery System | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPH204T | Formulation Development of Pharmaceutical and Cosmetic Products | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPH205PA | Pharmaceutics Practical I | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| MPH205PB | Pharmaceutics Practical I | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| - | Seminar/Assignment | - | - | - | - | - | - | 100 |
| Total | | | | | | | | 650 |

Tables – 17: Schemes for internal assessments and end semester (Industrial Pharmacy- MIP)

| Course Code | Course | Internal Assessment | | | | End Semester Exams | | Total Marks |
|--------------------|--|---------------------|-----------------|----------|-------|--------------------|----------|-------------|
| | | Continues Mode | Sessional Exams | | Total | Marks | Duration | |
| | | | Marks | Duration | | | | |
| SEMESTER I | | | | | | | | |
| MIP101T | Modern Pharmaceutical Analytical Techniques | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MIP102T | Pharmaceutical Formulation Development | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MIP103T | Novel Drug Delivery Systems | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MIP104T | Intellectual Property rights | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MIP105PA | Industrial Pharmacy Practical I | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| MIP105PB | Industrial Pharmacy Practical II | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| - | Seminar/Assignment | - | - | - | - | - | - | 100 |
| Total | | | | | | | | 650 |
| SEMESTER II | | | | | | | | |
| MIP201T | Advanced Biopharmaceutics and Pharmacokinetics | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MIP202T | Scale up and Technology Transfer | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MIP203T | Pharmaceutical Production Technology | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MIP204T | Entrepreneurship Management | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MIP205PA | Industrial Pharmacy Practical III | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| MIP205PB | Industrial Pharmacy Practical IV | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| - | Seminar/Assignment | - | - | - | - | - | - | 100 |
| Total | | | | | | | | 650 |

Tables – 18: Schemes for internal assessments and end semester (Pharmaceutical Chemistry- MPC)

| Course Code | Course | Internal Assessment | | | | End Semester Exams | | Total Marks |
|--------------------|---|---------------------|-----------------|----------|-------|--------------------|----------|-------------|
| | | Continues Mode | Sessional Exams | | Total | Marks | Duration | |
| | | | Marks | Duration | | | | |
| SEMESTER I | | | | | | | | |
| MPC101T | Modern Pharmaceutical Analytical Techniques | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPC102T | Advanced Organic Chemistry – I | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPC103T | Advanced Medicinal Chemistry | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPC104T | Chemistry of Natural Products | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPC105PA | Pharmaceutical chemistry Practical I | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| MPC105PB | Pharmaceutical chemistry Practical II | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| | Seminar/Assignment | - | - | - | - | - | - | 100 |
| Total | | | | | | | | 650 |
| SEMESTER II | | | | | | | | |
| MPC201T | Advanced Spectral Analysis | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPC202T | Advanced Organic Chemistry II | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPC203T | Computer Aided Drug Design | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPC204T | Pharmaceutical Process Chemistry | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPC205PA | Pharmaceutical chemistry Practical III | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| MPC205PB | Pharmaceutical chemistry Practical IV | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| | Seminar/Assignment | - | - | - | - | - | - | 100 |
| Total | | | | | | | | 650 |

Tables – 19: Schemes for internal assessments and end semester (Pharmaceutical Analysis- MPA)

| Course Code | Course | Internal Assessment | | | | End Semester Exams | | Total Marks |
|--------------------|---|---------------------|-----------------|----------|-------|--------------------|----------|-------------|
| | | Continues Mode | Sessional Exams | | Total | Marks | Duration | |
| | | | Marks | Duration | | | | |
| SEMESTER I | | | | | | | | |
| MPA101T | Modern Pharmaceutical Analytical Techniques | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPA102T | Advanced Pharmaceutical Analysis | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPA103T | Pharmaceutical Validation | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPA104T | Food Analysis | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPA105PA | Pharmaceutical Analysis Practical I | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| MPA105PB | Pharmaceutical Analysis Practical II | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| | Seminar/Assignment | - | - | - | - | - | - | 100 |
| Total | | | | | | | | 650 |
| SEMESTER II | | | | | | | | |
| MPA201T | Advanced Instrumental Analysis | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPA202T | Modern Bio-Analytical Techniques | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPA203T | Quality Control and Quality Assurance | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPA204T | Herbal and Cosmetic Analysis | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPA205PA | Pharmaceutical Analysis Practical III | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| MPA205PB | Pharmaceutical Analysis Practical IV | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| | Seminar/Assignment | - | - | - | - | - | - | 100 |
| Total | | | | | | | | 650 |

Tables – 20: Schemes for internal assessments and end semester (Pharmaceutical Quality Assurance- MQA)

| Course Code | Course | Internal Assessment | | | | End Semester Exams | | Total Marks |
|--------------------|--|---------------------|-----------------|----------|-------|--------------------|----------|-------------|
| | | Continues Mode | Sessional Exams | | Total | Marks | Duration | |
| | | | Marks | Duration | | | | |
| SEMESTER I | | | | | | | | |
| MQA101T | Modern Pharmaceutical Analytical Techniques | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MQA102T | Quality Management System | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MQA103T | Quality Control and Quality Assurance | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MQA104T | Product Development and Technology Transfer | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MQA105PA | Pharmaceutical Quality Assurance Practical I | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| MQA105PB | Pharmaceutical Quality Assurance Practical II | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| | Seminar/Assignment | - | - | - | - | - | - | 100 |
| Total | | | | | | | | 650 |
| SEMESTER II | | | | | | | | |
| MQA201T | Hazards and Safety Management | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MQA202T | Pharmaceutical Validation | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MQA203T | Audits and Regulatory Compliance | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MQA204T | Pharmaceutical Manufacturing Technology | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MQA205PA | Pharmaceutical Quality Assurance Practical III | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| MQA205PB | Pharmaceutical Quality Assurance Practical IV | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| | Seminar/Assignment | - | - | - | - | - | - | 100 |
| Total | | | | | | | | 650 |

Tables – 21: Schemes for internal assessments and end semester (Pharmaceutical Regulatory Affairs- MRA)

| Course Code | Course | Internal Assessment | | | | End Semester Exams | | Total Marks |
|--------------------|---|---------------------|-----------------|----------|-------|--------------------|----------|-------------|
| | | Continues Mode | Sessional Exams | | Total | Marks | Duration | |
| | | | Marks | Duration | | | | |
| SEMESTER I | | | | | | | | |
| MRA101T | Good Regulatory Practices | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MRA102T | Documentation and Regulatory Writing | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MRA103T | Clinical Research Regulations | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MRA104T | Regulations and Legislations for Drugs & Cosmetics, Medical Devices, Biologicals & Herbals, and Food & Nutraceuticals in India and Intellectual Property Rights | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MRA105PA | Regulatory Affairs Practicals I | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| MRA105PB | Regulatory Affairs Practicals II | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| | Seminar/Assignment | - | - | - | - | - | - | 100 |
| Total | | | | | | | | 650 |
| SEMESTER II | | | | | | | | |
| MRA201T | Regulatory Aspects of Drugs and Cosmetics | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MRA202T | Regulatory Aspects of Herbal & Biologicals | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MRA203T | Regulatory Aspects of Medical Devices | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MRA204T | Regulatory Aspects of Food Nutraceuticals | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MRA205PA | Regulatory Affairs Practicals III | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| MRA205PB | Regulatory Affairs Practicals IV | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| | Seminar/Assignment | - | - | - | - | - | - | 100 |
| Total | | | | | | | | 650 |

Tables – 22: Schemes for internal assessments and end semester (Pharmaceutical Biotechnology-MPB)

| Course Code | Course | Internal Assessment | | | | End Semester Exams | | Total Marks |
|--------------------|---|---------------------|-----------------|----------|-------|--------------------|----------|-------------|
| | | Continues Mode | Sessional Exams | | Total | Marks | Duration | |
| | | | Marks | Duration | | | | |
| SEMESTER I | | | | | | | | |
| MPB101T | Modern Pharmaceutical Analytical Techniques | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPB102T | Microbial and Cellular Biology | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPB103T | Bioprocess Engineering and Technology | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPB104T | Advanced Pharmaceutical Biotechnology | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPB105PA | Pharmaceutical Biotechnology Practical I | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| MPB105PB | Pharmaceutical Biotechnology Practical II | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| | Seminar/Assignment | - | - | - | - | - | - | 100 |
| Total | | | | | | | | 650 |
| SEMESTER II | | | | | | | | |
| MPB201T | Proteins and Protein Formulation | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPB202T | Immunotechnology | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPB203T | Bioinformatics and Computer Technology | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPB204T | Biological Evaluation of Drug Therapy | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPB205PA | Pharmaceutical Biotechnology Practical III | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| MPB205PB | Pharmaceutical Biotechnology Practical IV | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| | Seminar/Assignment | - | - | - | - | - | - | 100 |
| Total | | | | | | | | 650 |

Tables – 23: Schemes for internal assessments and end semester (Pharmacy Practice- MPP)

| Course Code | Course | Internal Assessment | | | | End Semester Exams | | Total Marks |
|--------------------|---|---------------------|-----------------|----------|-------|--------------------|----------|-------------|
| | | Continues Mode | Sessional Exams | | Total | Marks | Duration | |
| | | | Marks | Duration | | | | |
| SEMESTER I | | | | | | | | |
| MPP101T | Clinical Pharmacy Practice | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPP102T | Pharmacotherapeutics - I | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPP103T | Hospital & Community Pharmacy | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPP104T | Clinical Research | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPP105PA | Pharmacy Practice Practical I | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| MPP105PB | Pharmacy Practice Practical II | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| | Seminar/Assignment | - | - | - | - | - | - | 100 |
| Total | | | | | | | | 650 |
| SEMESTER II | | | | | | | | |
| MPP201T | Principles of Quality Use of Medicines | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPP202T | Pharmacotherapeutics - II | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPP203T | Clinical Pharmacokinetics and Therapeutic Drug Monitoring | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPP204T | Pharmacoepidemiology & Pharmacoeconomics | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPP205PA | Pharmacy Practice Practical III | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| MPP205PB | Pharmacy Practice Practical IV | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| | Seminar/Assignment | - | - | - | - | - | - | 100 |
| Total | | | | | | | | 650 |

Tables – 24: Schemes for internal assessments and end semester (Pharmacology- MPL)

| Course Code | Course | Internal Assessment | | | | End Semester Exams | | Total Marks |
|--------------------|---|---------------------|-----------------|----------|-------|--------------------|----------|-------------|
| | | Continues Mode | Sessional Exams | | Total | Marks | Duration | |
| | | | Marks | Duration | | | | |
| SEMESTER I | | | | | | | | |
| MPL101T | Modern Pharmaceutical Analytical Techniques | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPL102T | Advanced Pharmacology - I | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPL103T | Pharmacology and Toxicology Screening methods- I | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPL104T | Cellular and Molecular Pharmacology | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPL105PA | Pharmacology Practical I | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| MPL105PB | Pharmacology Practical II | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| | Seminar/Assignment | - | - | - | - | - | - | 100 |
| Total | | | | | | | | 650 |
| SEMESTER II | | | | | | | | |
| MPL201T | Advanced Pharmacology - II | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPL202T | Pharmacology and Toxicology Screening methods- II | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPL203T | Principles of Drug Discovery | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPL204T | Experimental Pharmacology Practical II | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPL205PA | Pharmacology Practical III | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| MPL205PB | Pharmacology Practical IV | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| | Seminar/Assignment | - | - | - | - | - | - | 100 |
| Total | | | | | | | | 650 |

Tables – 25: Schemes for internal assessments and end semester (Pharmacognosy- MPG)

| Course Code | Course | Internal Assessment | | | | End Semester Exams | | Total Marks |
|--------------------|---|---------------------|-----------------|----------|-------|--------------------|----------|-------------|
| | | Continues Mode | Sessional Exams | | Total | Marks | Duration | |
| | | | Marks | Duration | | | | |
| SEMESTER I | | | | | | | | |
| MPG101T | Modern Pharmaceutical Analytical Techniques | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPG102T | Advanced Pharmacognosy - I | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPG103T | Phytochemistry | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPG104T | Industrial Pharmacognostical Technology | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPG105PA | Pharmacognosy Practical I | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| MPG105PB | Pharmacognosy Practical II | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| | Seminar/Assignment | - | - | - | - | - | - | 100 |
| Total | | | | | | | | 650 |
| SEMESTER II | | | | | | | | |
| MPG201T | Medicinal Plant Biotechnology | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPG202T | Advanced Pharmacognosy - II | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPG203T | Indian system of Medicine | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPG204T | Herbal Cosmetics | 10 | 15 | 1Hr | 25 | 75 | 3Hr | 100 |
| MPG205PA | Pharmacognosy Practical III | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| MPG205PB | Pharmacognosy Practical IV | 10 | 15 | 3Hr | 25 | 50 | 3Hr | 75 |
| | Seminar/Assignment | - | - | - | - | - | - | 100 |
| Total | | | | | | | | 650 |

Tables – 26: Schemes for internal assessments and end semester examinations (Semester III & IV)

| Course Code | Course | Internal Assessment | | | | End Semester Exams | | Total Marks |
|---------------------|---|---------------------|-----------------|----------|-------|--------------------|----------|-------------|
| | | Continuous Mode | Sessional Exams | | Total | Marks | Duration | |
| | | | Marks | Duration | | | | |
| SEMESTER III | | | | | | | | |
| MRM301T | Research Methodology and Biostatistics* | 10 | 15 | 1 Hr | 25 | 75 | 3 Hrs | 100 |
| - | Journal club | . | . | . | 25 | . | . | 25 |
| - | Discussion / Presentation (Proposal Presentation) | . | . | . | 50 | . | . | 50 |
| - | Research work* | . | . | . | . | 350 | 1 Hr | 350 |
| Total | | | | | | | | 525 |
| SEMESTER IV | | | | | | | | |
| - | Journal club | . | . | . | 25 | . | . | 25 |
| - | Discussion / Presentation (Proposal Presentation) | . | . | . | 75 | . | . | 75 |
| - | Research work and Colloquium | . | . | . | . | 400 | 1 Hr | 400 |
| Total | | | | | | | | 500 |

*Non University Examination

11.2. Internal assessment: Continuous mode

The marks allocated for Continuous mode of Internal Assessment shall be awarded as per the scheme given below.

Table – 27: Scheme for awarding internal assessment: Continuous mode

| Theory | |
|---|---------------|
| Criteria | Maximum Marks |
| Attendance (Refer Table – 28) | 8 |
| Student – Teacher interaction | 2 |
| Total | 10 |
| Practical | |
| Attendance (Refer Table – 28) | 10 |
| Based on Practical Records, Regular viva voce, etc. | 10 |
| Total | 20 |

Table – 28: Guidelines for the allotment of marks for attendance

| Percentage of Attendance | Theory | Practical |
|--------------------------|--------|-----------|
| 95 – 100 | 8 | 10 |
| 90 – 94 | 6 | 7.5 |
| 85 – 89 | 4 | 5 |
| 80 – 84 | 2 | 2.5 |
| Less than 80 | 0 | 0 |

11.2.1. Sessional Exams

Two sessional exams shall be conducted for each theory / practical course as per the schedule fixed by the college(s). The scheme of question paper for theory and practical sessional examinations is given in the table. The average marks of two sessional exams shall be computed for internal assessment as per the requirements given in tables.

12. Promotion and award of grades

A student shall be declared PASS and eligible for getting grade in a course of M.Pharm programme if he/she secures at least 50% marks in that particular course including internal assessment.

13. Carry forward of marks

In case a student fails to secure the minimum 50% in any Theory or Practical course as specified in 12, then he/she shall reappear for the end semester examination of that course. However his/her marks of the Internal Assessment shall be carried over and he/she shall be entitled for grade obtained by him/her on passing.

14. Improvement of internal assessment

A student shall have the opportunity to improve his/her performance only once in the sessional exam component of the internal assessment. The re-conduct of the sessional exam shall be completed before the commencement of next end semester theory examinations.

15. Reexamination of end semester examinations

Reexamination of end semester examination shall be conducted as per the schedule given in table 29. The exact dates of examinations shall be notified from time to time.

Table – 29: Tentative schedule of end semester examinations

| Semester | For Regular Candidates | For Failed Candidates |
|-----------|------------------------|-----------------------|
| I and III | November / December | May / June |
| II and IV | May / June | November / December |

16. Allowed to keep terms (ATKT):

No student shall be admitted to any examination unless he/she fulfills the norms given in 6. ATKT rules are applicable as follows:

A student shall be eligible to carry forward all the courses of I and II semesters till the III semester examinations. However, he/she shall not be eligible to attend the courses of IV semester until all the courses of I, II and III semesters are successfully completed.

A student shall be eligible to get his/her CGPA upon successful completion of the courses of I to IV semesters within the stipulated time period as per the norms.

Note: Grade AB should be considered as failed and treated as one head for deciding ATKT. Such rules are also applicable for those students who fail to register for examination(s) of any course in any semester.

17. Grading of performances

17.1. Letter grades and grade points allocations:

Based on the performances, each student shall be awarded a final letter grade at the end of the semester for each course. The letter grades and their corresponding grade points are given in Table – 30.

Table–30: Letter grades and grade points equivalent to Percentage of marks and performances.

| Percentage of Marks Obtained | Letter Grade | Grade Point | Performance |
|------------------------------|--------------|-------------|-------------|
| 90.00 – 100 | O | 10 | Outstanding |
| 80.00 – 89.99 | A | 9 | Excellent |
| 70.00 – 79.99 | B | 8 | Good |
| 60.00 – 69.99 | C | 7 | Fair |
| 50.00 – 59.99 | D | 6 | Average |
| Less than 50 | F | 0 | Fail |
| Absent | AB | 0 | Fail |

A learner who remains absent for any end semester examination shall be assigned a letter grade of AB and a corresponding grade point of zero. He/she should reappear for the said evaluation/examination in due course.

18. The Semester grade point average (SGPA)

The performance of a student in a semester is indicated by a number called ‘Semester Grade Point Average’ (SGPA). The SGPA is the weighted average of the grade points obtained in all the courses by the student during the semester. For example, if a student takes five courses (Theory/Practical) in a semester with credits C₁, C₂, C₃ and C₄ and the student’s grade points in these courses are G₁, G₂, G₃ and G₄, respectively, and then students’ SGPA is equal to:

$$\text{SGPA} = \frac{C_1G_1 + C_2G_2 + C_3G_3 + C_4G_4}{C_1 + C_2 + C_3 + C_4}$$

The SGPA is calculated to two decimal points. It should be noted that, the SGPA for any semester shall take into consideration the F and ABS grade awarded in that semester. For example if a learner has a F or ABS grade in course 4, the SGPA shall then be computed as:

$$SGPA = \frac{C_1G_1 + C_2G_2 + C_3G_3 + C_4 \cdot \text{ZERO}}{C_1 + C_2 + C_3 + C_4}$$

19. Cumulative Grade Point Average (CGPA)

The CGPA is calculated with the SGPA of all the IV semesters to two decimal points and is indicated in final grade report card/final transcript showing the grades of all IV semesters and their courses. The CGPA shall reflect the failed status in case of F grade(s), till the course(s) is/are passed. When the course(s) is/are passed by obtaining a pass grade on subsequent examination(s) the CGPA shall only reflect the new grade and not the fail grades earned earlier. The CGPA is calculated as:

$$CGPA = \frac{C_1S_1 + C_2S_2 + C_3S_3 + C_4S_4}{C_1 + C_2 + C_3 + C_4}$$

where C_1, C_2, C_3, \dots is the total number of credits for semester I, II, III, \dots and S_1, S_2, S_3, \dots is the SGPA of semester I, II, III, \dots .

20. Declaration of class

The class shall be awarded on the basis of CGPA as follows:

First Class with Distinction = CGPA of 7.50 and above

First Class = CGPA of 6.00 to 7.49

Second Class = CGPA of 5.00 to 5.99

21. Project work

All the students shall undertake a project under the supervision of a teacher in Semester III to IV and submit a report. 4 copies of the project report shall be submitted (typed & bound copy not less than 75 pages).

The internal and external examiner appointed by the University shall evaluate the project at the time of the Practical examinations of other semester(s). The projects shall be evaluated as per the criteria given below.

Evaluation of Dissertation Book:

| | |
|-------------------------------|------------------|
| Objective(s) of the work done | 50 Marks |
| Methodology adopted | 150 Marks |
| Results and Discussions | 250 Marks |
| Conclusions and Outcomes | 50 Marks |
| Total | 500 Marks |

Evaluation of Presentation:

| | |
|----------------------------|------------------|
| Presentation of work | 100 Marks |
| Communications skills | 50 Marks |
| Question and answer skills | 100 Marks |
| Total | 250 Marks |

22. Award of Ranks

Ranks and Medals shall be awarded on the basis of final CGPA. However, candidates who fail in one or more courses during the M.Pharm program shall not be eligible for award of ranks. Moreover, the candidates should have completed the M. Pharm program in minimum prescribed number of years, (two years) for the award of Ranks.

23. Award of degree

Candidates who fulfill the requirements mentioned above shall be eligible for award of degree during the ensuing convocation.

24. Duration for completion of the program of study

The duration for the completion of the program shall be fixed as double the actual duration of the program and the students have to pass within the said period, otherwise they have to get fresh Registration.

25. Revaluation I Retotaling of answer papers

There is no provision for revaluation of the answer papers in any examination. However, the candidates can apply for retotaling by paying prescribed fee.

26. Re-admission after break of study

Candidate who seeks re-admission to the program after break of study has to get the approval from the university by paying a condonation fee.

Website: www.jntuk.edu.in

Email: dap@jntuk.edu.in



Phone: 7032894555

Directorate of Academic Planning
JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY KAKINADA
KAKINADA-533003, Andhra Pradesh, INDIA
(Established by AP Government Act No. 30 of 2008)

Lr. No. JNTUK/DAP/RAC/I Year/M.Pharmacy/2022-23

Date: 08-12-2022

Dr. KVSG Murali Krishna,

M.E. Ph.D.

Director, Academic Planning
JNTUK, Kakinada

To

All the Principals of Affiliated Colleges,
JNTUK, Kakinada.

Revised Academic Calendar of I Year M. Pharmacy
Academic year 2022-23

| I SEMESTER | | | |
|--|------------|------------|-------|
| Description | From | To | Weeks |
| Commencement of Class Work | 12.12.2022 | | |
| Induction Classes | 12.12.2022 | 17.11.2022 | 1W |
| I Unit of Instruction | 19.12.2022 | 11.02.2023 | 8W |
| I Mid Examinations | 06.02.2023 | 11.02.2023 | |
| II Unit of Instructions | 13.02.2023 | 08.04.2023 | 8W |
| II Mid Examinations | 03.04.2023 | 08.04.2023 | |
| Preparation & Practicals | 10.04.2023 | 15.04.2023 | 1W |
| End Examinations | 17.04.2023 | 29.04.2023 | 2W |
| Commencement of II Semester Class Work | 01.05.2023 | | |
| II SEMESTER | | | |
| Commencement of Class Work | 01.05.2023 | | |
| I Unit of Instructions | 01.05.2023 | 24.06.2023 | 8W |
| I Mid Examinations | 26.06.2023 | 24.06.2023 | |
| II Unit of Instructions | 26.06.2023 | 19.08.2023 | 8W |
| II Mid Examinations | 14.08.2022 | 19.08.2023 | |
| Preparation & Practicals | 21.08.2023 | 26.08.2023 | 1W |
| End Examinations | 28.08.2023 | 10.09.2023 | 2W |
| Commencement of Class Work | 12.09.2023 | | |

KVSG
24-12-22

Director Academics & Planning
JNTUK Kakinada, Director
Academic Planning
JNTUK Kakinada

Copy to the Secretary to the Hon'ble Vice Chancellor, JNTUK

Copy to PA, JNTUK

Copy to the Registrar, JNTUK

Copy to the Director of Audit, JNTUK

Copy to the Director of Extension, JNTUK



alt
PRINCIPAL

**VIJAYA INSTITUTE OF
PHARMACEUTICAL SCIENCES FOR WOMEN
NIKEPADU, VIJAYAWADA 528 108**

**INSTITUTIONAL EXAMINATION
COMMITTEE**







VIJAYA INSTITUTE OF PHARMACEUTICAL SCIENCES FOR WOMEN
Enikepadu, Vijayawada – 521108

Date: 26-07-2021

OFFICE ORDER

INSTITUTIONAL EXAMINATION COMMITTEE

The Institutional Examination Committee for the academic year 2021 – 2022 is constituted as follows and it is effective for a period of 06-09-2021 to 06-08-2022. Following staff members are appointed as Institutional Examination Committee.


| S.NO | NAME | DESIGNATION | POSITION | SIGNATURE |
|------|-------------------------|------------------|-----------------------------|---|
| 1 | Dr. K. Padmalatha | Principal | Chairman |  |
| 2 | Mr. S. Venkateswara Rao | Assoc. Professor | College Examination Officer |  |
| 3 | Mr. A. Jayarami Reddy | Assoc. Professor | Member |  |
| 4 | Mrs. A.V.S. Hima bindu | Asst. Professor | Member |  |
| 5 | Dr. N. Prathibha | Asst. Professor | Member |  |
| 6 | Dr. S. Sundar | Professor | Member |  |

Functions and Responsibilities:

1. Ensure proper dissemination of information with regard to examination among all the stakeholders' viz. students / faculty / non – teaching staff / university authorities etc.
2. Receive and submission of exam notification / schedule from JNTUK web portal.
3. To ensure proper organization of in semester assessments / sessional / end semester examinations in the college.
4. Ensure proper communication with JNTUK with regards to examination and fulfillment of university circulars.
5. Appoint alternative external senior supervisor / chairman / internal examiners / external examiners for conduct of end semester theory / practical examination with permission of university authorities.
6. Record and issue the answer books and other exam related stationary to the invigilators / internal examiners 30 minutes before start the exam
7. Download and print the appropriate number of question papers at least 20 minutes before the commencement of the exam and maintaining absolute confidentiality
8. Resolve students / faculty / university grievances with regards to examinations.
9. Uploading internal theory / practical examination marks on JNTUK web portal.
10. Maintain records with regards to conduct of examination and results.

Copy to: 1. Establishment File
2. Concerned Faculty member




Dr. K. Padmalatha
PRINCIPAL

VIJAYA INSTITUTE OF
PHARMACEUTICAL SCIENCES FOR WOMEN
ENIKEPADU, VIJAYAWADA - 521 108



JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY KAKINADA

UNIVERSITY EXAMINATION CENTER, KAKINADA


M. PHARMACY I SEMESTER (PCI REGULATION) I MID EXAMINATIONS, FEBRUARY - 2023

TIME TABLE

TIME: 10:00 AM TO 12:00 NOON

| BRANCH & SPECIALIZATION | 06-02-2023 (Monday) | 07-02-2023 (Tuesday) | 08-02-2023 (Wednesday) | 09-02-2023 (Thursday) |
|-------------------------------|---|--|---|---|
| PHARMACEUTICAL CHEMISTRY (02) | Modern Pharmaceutical Analytical Techniques (MPC101T) | Advanced Organic Chemistry -I (MPC102T) | Advanced Medicinal Chemistry (MPC103T) | Chemistry of Natural Products (MPC104T) |
| PHARMACEUTICS (03) | Modern Pharmaceutical Analytical Techniques (MPH101T) | Drug Delivery Systems (MPH102T) | Modern Pharmaceutics (MPH103T) | Regulatory Affairs (MPH104T) |
| PHARMACOLOGY (06) | Modern Pharmaceutical Analytical Techniques (MPL101T) | Advanced Pharmacology-I (MPL102T) | Pharmacological and Toxicological Screening Methods-I (MPL103T) | Cellular and Molecular Pharmacology (MPL104T) |
| PHARMACOGNOSY (07) | Modern Pharmaceutical Analytical Techniques (MPG101T) | Advanced Pharmacognosy-I (MPG102T) | Phytochemistry (MPG103T) | Industrial Pharmacognostical Technology (MPG104T) |
| PHARMACY PRACTICE (08) | Clinical Pharmacy Practice (MPP101T) | Pharmacotherapeutics-I (MPP102T) | Hospital & Community Pharmacy (MPP103T) | Clinical Research (MPP104T) |
| INDUSTRIAL PHARMACY (09) | Modern Pharmaceutical Analytical Techniques (MIP101T) | Pharmaceutical Formulation Development (MIP102T) | Novel drug delivery systems (MIP103T) | Intellectual Property Rights (MIP104T) |




PRINCIPAL
VIJAYA INSTITUTE OF
PHARMACEUTICAL SCIENCES FOR WOMEN
ENIKEPADU, VIJAYAWADA - 521 108

| BRANCH & SPECIALIZATION | 06-02-2023 (Monday) | 07-02-2023 (Tuesday) | 08-02-2023 (Wednesday) | 09-02-2023 (Thursday) |
|--|---|--|---|--|
| PHARMACEUTICAL REGULATORY AFFAIRS (13) | Good Regulatory Practices (MRA101T) | Documentation and Regulatory Writing (MRA102T) | Clinical Research Regulations (MRA103T) | Regulations and Legislation for Drugs & Cosmetics, Medical Devices, Biologicals & Herbals, and Food & Nutraceuticals In India and Intellectual Property Rights (MRA104T) |
| PHARMACY QUALITY ASSURANCE (15) | Modern Pharmaceutical Analytical Techniques (MQA101T) | Quality Management System (MQA102T) | Quality Control and Quality Assurance (MQA103T) | Product Development and Technology Transfer (MQA104T) |
| PHARMACEUTICAL ANALYSIS (16) | Modern Pharmaceutical Analytical Techniques (MPA101T) | Advanced Pharmaceutical Analysis (MPA102T) | Pharmaceutical Validation (MPA103T) | Food Analysis (MPA104T) |

- NOTE: (i) If Government declares holiday on any of the above dates, the examinations will be conducted as usual
(ii) Any omissions or clashes in this Time Table may please be informed to the Controller of Examinations immediately.
(iii) The Principals are requested to inform the University, if any other substitute subjects that are not included in the above time table immediately

Date: 27-01-2023



S. Venkatesh
28/01/2023

atta
28/1/23
PRINCIPAL

VIJAYA INSTITUTE OF
PHARMACEUTICAL SCIENCES FOR WOMEN
ENIKEPADU, VIJAYAWADA-521 108.





[Signature]


Controller of Examinations (PG)

**VIJAYA INSTITUTE OF PHARMCEUTICAL SCIENCES FOR WOMEN
ENIKEPADU, VIJAYAWADA – 521108.**

I M. Pharm I Sem I Mid Exams Invigilation Duties, Feb-2023

Timings : 10:00 AM TO 12:00 PM

| Exam Dates | Staff Name | Staff Signature |
|----------------------------|-------------------------|---|
| 06.02.2023 (Monday) | Mrs. K. V. R. Rajeswari |  |
| 07.02.2023 (Tuesday) | Ms. B. Lekhya |  |
| 08.02.2023 (Wednesday) | Dr. B. Dhanush |  |
| 09.02.2023 (Thursday) | Mrs. K. V. R. Rajeswari |  |


Exams Incharge
(Dr. S. Venkateswara Rao)
EXAMS-INCHARGE
VIJAYA INSTITUTE
PHARMACEUTICAL SCIENCES FOR WOMEN
ENIKEPADU VIJAYAWADA 521 108


Principal
(Dr. K. Padmalatha)
PRINCIPAL
VIJAYA INSTITUTE OF
PHARMACEUTICAL SCIENCES FOR WOMEN
ENIKEPADU, VIJAYAWADA - 521 108



INTERNAL SQUAD COMMITTEE






VIJAYA INSTITUTE OF PHARMACEUTICAL SCIENCES FOR WOMEN
Enikepadu, Vijayawada – 521108

Date: 26-07-2021

OFFICE ORDER

INTERNAL SQUAD COMMITTEE

The Internal Squad Committee has been constructed for smooth conduct of sessional / end semester examinations for the academic year 2021 – 2022 for the period of 06-09-2021 to 06-08-2022. Following staff members are appointed as Internal Squad Committee.


| S.NO | NAME | DESIGNATION | POSITION | SIGNATURE |
|------|-------------------------|------------------|-----------|---|
| 1 | Dr. K. Padmalatha | Principal | President |  |
| 2 | Mr. S. Venkateswara Rao | Assoc. Professor | Chairman |  |
| 3 | Mr. A. Jayarami Reddy | Asst. Professor | Member |  |
| 4 | Mrs. A.V.S. Hima bindu | Asst. Professor | Member |  |
| 5 | Mrs. Ch. Anupama Swathi | Asst. Professor | Member |  |

Responsibilities:

1. Strict checking of unfair means is sole responsibility of members of committee.
2. Before the start of examination, the committee members should check every student.
3. Care should be taken by committee members, that the students should not carry mobile phones, calculator or any sort of electronic material inside the examination hall.
4. Check whether students are carrying hall tickets by committee members to maintain environment of examination. Any issue related to the unfair means should immediately report to the principal or college examination officer.

Copy to: 1. Establishment File
2. Concerned Faculty member




Dr. K. Padmalatha
PRINCIPAL
VIJAYA INSTITUTE OF
PHARMACEUTICAL SCIENCES FOR WOMEN
ENIKEPADU, VIJAYAWADA - 521

I MID

ATTENDANCE SHEET FOR I MID EXAMINATIONS

COURSE: M. Pharm

Date of Examination: 08.02.23

Time: 10.00 AM TO 12.00 PM

Room No: 01

Subject Name: Pharmacological & Toxicological Screening Methods-I

Subject Code: MPL103T

No. of Students Present: 02

No. of Students Absent: 01

| S.No. | Hall Ticket No. | Name of the Student | Answer Booklet Serial No. | Signature of the Student |
|-------|-----------------|----------------------|---------------------------|--------------------------|
| 1 | 227N1S0601 | BOYALAPALLI PRASANNA | 7N220001 | B. Prasanna . |
| 2 | 227N1S0602 | CHALAMALA RAMYANJALI | 7N220002 | Ch. Ramyanjali |
| 3 | 227N1S0603 | SHAIK HAFSA | 7N220003 | — ABSENT — |

Signature of the Invigilator: B. Dhanush

Name of the Invigilator: B. DHANUSH.

Designation: ASST. PROFESSOR



Handwritten signature of the Principal in green ink.

Signature of the Principal

PRINCIPAL
VIJAYA INSTITUTE O.
PHARMACEUTICAL SCIENCES FOR WOMEN
ENIKEPADU, VIJAYAWADA - 521 108

Model of Evaluated Mid Exam
Answer Script

SRK FOUNDATION'S
**VIJAYA INSTITUTE OF
PHARMACEUTICAL SCIENCES FOR WOMEN**

ENIKEPADU, VIJAYAWADA



20~~22~~²³ - 20~~23~~²³

SESSIONAL BOOK

Name : B. Prasanna
Class : 1st M. pharmacy [pharmacology dept]
Roll No. : 227N150601
Subject : Pharmacological & Toxicological Screening models-I

| Internal | Objective | Subjective | Assignment | Total | Staff Sign | Student Sign |
|----------|-----------|------------|------------|--------|------------|--------------|
| I | | 21 | | 21 | | B. Prasanna |
| II | | 23 1/2 | | 23 1/2 | | B. Prasanna |

Final Average : 22

Staff Sign

HOD Sign

I
1) Predinical Evaluation of drugs for Alzheimer's disease.

In vitro

1) Adenylcyclase activity

In vivo

1) Step down

2) Two compartment Test

3) Radial arm maze Study

4) Water maze Study

Step down

Mice or rat either sex



Test Std / Test compound orally



Animal is placed on a platform containing rectangular box with floor grids, these grids are attached to shocking device to deliver the foot shock.



Measure Step down assay / latency period.



After finished the experiment the animal step down or remain is recorded.

21
30

Two Compartment Test

Mice or rat either Sex



It should contain 50x50 cm rectangular box with removal ceiling 35° cm this is connected with small box 15x15² cm with black walls.



These two compartments has transparent slight door is present between of the compartments.



Illuminating with 100 w bulb at the centre of large compartment



Latency is measured.

Radial arm maze Study

Mice or rat either Sex



apparatus is wooden, consists elevated as 8 radial arm maze with 56 long length, 5 cm wide, 2 cm height



Animal is placed on the apparatus & food is attached to maze.



During test animal food should be provide per day at once, wgt should be maintained at 85.

↓
Trained the animals to run in maze to catch the pellets.

↓
Training is terminated after 8 choices, the animal obtained maximum of pellets with minimum of errors

↓
Errors is measure.

Water maze study

water tank filled with 20° depth & 25°c water.
Apparatus is circular, & it is divided (distributed) into 4 parts Served as starting point, with

↓
This apparatus is divided into 4 quadrants, small quadrant is fixed in the ^{center of} any one of the quadrant

↓
The quadrant (small) is placed on entire training sessions.

↓
The animal is allow in water upto 60-90 sec to findout the quadrant.

↓
Trained rats are identify the quadrant in less than 10 sec.

↓
After experiment, quadrant is removed & allow the animal in water to swim for 30 seconds.

Screening procedures for parasympathomimetic drugs

In vitro

- 1) Guinea pig Pleum.
- 2) Isolated eye of rodent.
- 3) To detect anticholinesterase activity.

In vivo

- 1) To detect anticholinesterase activity in rat.

Guinea pig Pleum

Guinea pig (250-500 gm)



Killed by Stunning



Abdomen cut & mid incision



Remove pancreas / intestine



Intestine is cut half & pass through glass is inserted into it.



Tyrod Solution is passed through & effluent the free of Substances.



Cut the pieces into (2-3) cm.

↓
One side piece is attached to tissue clamp & inserted into 10-20 ml of tissue bath & attached to writer lever.

↓
writer lever produces contractions 10-20 times.

↓
ACh (0.01 μg) is added.

↓
It produces ^{contractions of} 70-90% of maximal responses.

To detect anticholinesterase activity

Thiolester ACh is used as substrate

↓
To detect the inhibition of enzyme activity

2.89 ml of phosphate buffer

10 ml Sample

0.1 ml DTNB

↓
All are mixed & incubate for 10 minutes!

↓
Add substrate & measure the Spectrometry by using Spectrometry.

To detect anticholinesterase in cat

Cat (1-2 kg)

↓
Anesthetized with pentobarbitone

↓
Test Compound IV administer.

↓
Carotid artery is cannulated to detect BP

↓
occur different doses at ^{anti} cholinesterase activity
as follows.

at dose X: No detectable effects

at dose 2X: Slightly bronchial & fall in BP
to 10-20 mm Hg.

at dose 4X: Fall in BP to 50-100 mm Hg
it leads to

- 1) Initial rise in respiration & ↓ use in respiration.
- 2) Salivary & Bronchial Secretions Seen.
- 3) Urination -

II

3) Screening procedures for parkinson's disease

In vitro

- 1) Experiments using rats Striatal Slices.
- 2) Dopamine Stimulated ~~adenylate~~ anticholinesterase activity.

In vivo

- 1) Tremorine & Oxetremorine in rats/mice.
- 2) MPTP model in monkeys.
- 3) Reserpine antagonism in mice.
- 4) 6-Hydroxy dopamine induced neostriatal lyses in rats.

Tremorine & oxitremorine in rats / mice

Group of 6-10 male NMRI mice
(18-22g)



Test compound / standard is given orally.



After 24 hrs Oxitremorine (0.15 mg/kg) Subcutaneously administer.



Rectal Temperature is measured before administration & 1, 2, 4, 6 hrs after administration.



Record the signs like tremors, stupus etc...

MPTP model in monkeys

8 Adult rhesus monkeys
(5-8 kg)



Over a period of 8-10 days 20 doses of MPTP is administered.



Developed parkinson's symptoms.



This is reversible, ^(No symptoms) when test compound L-Dopa is administered



Check the actions / signs.

Reserpine antagonism in mice

Take NMRI mice (20-25g)



Administer drug 2P (10 mg/kg)



Reserpine (0.1 mg/kg)



3M ✓ Observation for 24 hrs.

↓ Reserpine inject.

produce horizontal movements for every 10 minutes



Rearing & Grooming is recorded by expert observer.

4 Preclinical Screening Principles of Sympatholytic drug

In vitro

- 1) Nictitating membrane prolapse in cat.
- 2) α & β adrenergic antagonism of mouse eye.

In vivo

- 1) Vas deference of rat.
- 2) Straited strip of cat.
- 3) To access the β_1 & β_2 adrenoreceptors of agonism & antagonism.

Vas deference of rat

Rat (1-2.5 gm)

↓

killed by Stunning

↓

Cut the abdomen & make the midline incision
to dissect the Vas deference.

↓

Tissue is suspend in tissue bath (Tyrode, aerated,
35°C)

↓

NA is added

↓

Phentolamine is used as Standard (∵ reduction of
activity of ~~β~~ adrenoreceptors).

Straital Strip of cat

Cat (2-3 kg)

↓

Anesthetized.

↓

Suspended in organ bath (Krebs, aerated, 38°C).

↓

Tension is added 0.5 mg, magnitude 5-6 times,
then NA/A is added then after add test
drug.

Pentolamine is used as standard drug (% reduction of activation of agonism & antagonism).

Niciating membrane prolapse in cats

Cats (Group 6-8 animals)
(2-3 kg)

↓
Anesthetized with pentobarbitone.

↓
Test compound adrenaline is administered

↓
It produces the relaxant activity

↓
Compare the animals with std.

↓
Continue the process with other animals with different concentrations.

Anesthesia

It is the drug to produce reversible loss of sensation

or consciousness.

→ Anesthesia is done by experts in lab.

→ So many anesthetics are available mainly used

1) Inhalatⁿ anesthetics.

2) Intravenous anesthetics.

→ When anesthesia is administered the animal is paralysed for some-time with artificial respiration is produced

- This is done at Experimental lab.
- Tension is avoid by patient, animal also feels fearless.
- Adequate results are not come due to tension.
- Care should be taken by expertian.
- He/she has experienced in cutting skills / insertion skills.
- Handle the animal with appropriate care.
- Cruelty is avoid deal carefully.
- Once animal is anesthetized incision is made & cut, take the part it should be placed at tissue suspended bath (organ bath).
- Done the stitches utmost care.
- Provide the nutritional food or saline liquids to recovery of animal.
- Tablets will be dissolve & given through oral route.
- If any cases it should not recover or unhealthy it should be immediately done by euthanasia.

Euthanasia

- The animal is gentle killing or death is called euthanasia.
- This is done for experimental work or research or

fermentation of organs. in labs.

→ This should be done by painless.

→ Euthanasia is done by ethical process.

→ Euthanasia is not in cruelty form.

→ Experiments are done almost without harming/euthanasia.

→ For euthanasia it has some rules & regulations.

→ Reason is compulsory for euthanasia is done.

→ maintain records.

6. Different Strains and species of laboratory animals

Rat

→ This the small animal in laboratory it should be breed equally, very sensitive to drugs.

→ Two inbred rats are used.

a) wistar rats

b) Albino rats

wistar rats

→ Head is wide, tail is long which is longer than body.

Albino rats

→ Head is long, narrow body tail is equal to body.

Some characteristics of rats

→ Rats has doesn't vomiting center that's why it can't vomit.

→ No gall bladder.

→ Mainly used for teratogenicity, mutagenicity & carcinogenicity.

Mouse

→ This is the smallest animal in laboratory, available as cheap.

→ Sensitive to drugs.

→ Determine by using teratogenicity.

Guinea pig

→ This is the dole & deal carefully.

→ It is sensitive to histamines & produce severe bronchoconstriction & asphyxia.

→ used in bioassay of digitalis & local anesthetics.

→ used in inflammatory drugs identification.

Hamster

Two types hamsters are present

1) Golden hamster.

2) Cricetus hamster.

This is chunky body, short legs, 5 toes in back, 4 toes in front.

Golden hamster is used for virology, cancer.

Cricetus hamster is used for antidiabetic, antipyretics.

→ mainly for immunology.

Rabbit

New Zealand ^{white} rabbit is mostly used.

It has long ears.

→ It is used for carcinogenicity & teratogenicity.

→ Mainly used for bioassay of digitalis.

Monkey

→ This is very resemble to human being physically.

Structurally it resembles man.

→ This brain is close to human brain.

→ mainly employed for Neuro disorders.

Cat

Cat is used for BP testing agents (anti hypertensives)
morphine is produce unconsciousness in cat.

→ Carotid artery is ~~fixed~~ to measure the bp.

Frog

→ It is aquatic amphibian animal.

→ mainly used for Neuro muscular junction problems

Transgenic animals

Mouse

→ The first animal

→ This is done by altering the gene of mother & insert into baby rat (egg), it should produce large size baby (size of mouse) than mother.

Goat

→ Take goat milk & make them milk for orphan babies to feed.

Sheep: (Dolly is the first clone baby).

→ wool is used for making textiles, pharmaceutical uses

Chicken

→ In ovum a new molecule is inserted large size hen is

Produce & it should be produce more eggs.

Fish

→ zebra-fishes are newly produced.

Calf, Buffalo

→ These milk are used for feed for in many products.

11

2. Screening methods of Antidiabetic and diuretic agents

234/2
30

- 1) Pancreatamy of dogs
- 2) Alloxan induced diabetes (Rabbit, Rat, Dog)
- 3) Streptozotocin induced diabetes (Rat)
- 4) Hormone induced Diabetic mellitus

Pancreatamy of Dogs

Male Beagil Dogs (12-16 Kg) → Anaesthetized with Pento Sodium barbitone IV (30 mg/kg) & placed on back → Open abdomen with care and with proper Surgical Skills

4/2

Both ends of pancreas are ligated

Small vessels of pancreas are ligated

Pancreas is brought into operating field & Separate the mesenteric attachments

The pyloric & splenic parts of pancreas are delivered into wounds

The mesentery body of pancreas & tail is separated & cut

After 19-20 hrs pancreas is dissected out by Sacrificing the animal

The pancreas is the only one part is to be dissected

The pancreatic branch of Splenic vessels are doubly ligated

The pancreatic tissue & Splenic vessel is ligated

↓
Finally pancreas is
to be dissected
out

→ The abdominal wall &
Superficial layer of
Skin is Sutured.

→ The drug dog is
treated with
post operative
Care.

3rd day give milk
& turn to normal
feed. ←
Insulin is replaced
with retard insulin.

↓
1 litre of glucose
& 10 IU of retard
Insulin & 1g of
metamizol.

Alloxan induced diabetes

Rabbit → New Zealand
Albino to rabbits
(2.5 - 4 kg)

→ Alloxan monohydrate
(5 kg/100 ml) is
infused.
100 - 150 mg/kg IV

→ 90% of animals
are hypoglycemic.

↓
Dog is used for
further screening.

Rat → Albino rats
(150 - 200g)

→ Alloxan monohydrate
100 - 175 mg/kg

→ Hyperglycemic

Dog → Male Beagil
rats
(12 - 16 kg)

→ IV 60 mg/kg
Alloxan monohydrate

→ Treated with
glucose &
Canned food

↓
Treated with single
Sc retard
Insulin.

Streptozotocin induced diabetics

Albino rats
(150-200g)

→ Test drug administer
through IV
(60 mg/kg)

→ Initially increase
glucose level in
150-200 mg/dl bcz of
increase blood
volume in 3 hrs.

After 12-14
days of

Steady State concentration
the animals are undergo
for screening tests.

Severity & Symptoms
of diabetics are depend on dose
of Streptozotocin.

↓
After 15-20 hrs. glucose
levels increase because
of increase in serum
of glucose.

Hormone induced diabetics

Deoxymethasone
(Long acting
Corticosteroid)

→ IV 2.5 mg/kg

→ 2DDM of
diabetics

3 Anti cancer drugs


In vitro

- 1) Tripan blue viability test
- 2) Alamar blue assay

In vivo

- Liver cancer induced by diethyl amino benzene
- Carcinogen induced models
- Viral infectⁿ models
- Transplantatⁿ models
- Hollow fibre

Liver Cancer induced by diethyl amino benzene



Carcinogen induced models

Mice only for single dose of 2.5 μ g of DNMB in acetone & 0-10 μ g of TPA in 0.2 ml in acetone

↓

Percent of carcinogen incidence & multiplicity of treatment

↳ - compared with DNMB controls.

↓

Test compound is given through intraperitoneally & oral.

↓

The percent of carcinogen is usually 100% of DNMB controls.

↓
DNMB alone give it induce Carcinogens.

↓
Reduce carcinogen is identify by reductⁿ of symptoms & efficacy of drug.

Viral infectⁿ models

→ The mouse mammary Tumour virus (MMTV) is isolated in Jackson laboratory identified as "Non-Chromosomal factor". & produce tumour in C₃H₃ Strain in mice.

→ Some viruses cause cancer via integratⁿ in certain cells.

→ Some viruses cause tumour by oncogenes.

Abelson murine leukemia virus.

Murine sarcoma virus.

→ Engineering viruses are used now routinely for inducing cancer.

Transplantatⁿ virus (models)

→ Tumour cells or tissues are implanted in a host mouse.

→ Ectopic - Implanted organ than in different organ.
Orthotopic - Implanted organ into analogous organ into original tumour.

In vivo hollow fibre assay 1.

- In vivo Screening tool introduced in 1955 by NCI.
- 12 human tumour cell lines (Breast, cancer, colon, melanoma & ovary)
- After in vivo treatment fibres are removed & analysed in vitro.
- In vivo assessed availability.

4. Preclinical screening principles of antiasthmatic drugs

In vitro

1) Isolated Guinea pig Lung Strips.

2) Isolated Guinea pig Trachea.

In vivo

1) Bronchospasmolytic activity in Guinea pig.

2) Broncho overactivity of Guinea pig.

Isolated Guinea pig Trachea.

Albino Guinea pig
(300-350g)

↓
Sacrificed with CO₂ necrosis.

↓

Entire Trachea is removed & cut into individual rings.

↓
All rings are held together by silk thread.

↓
Mounted to organ bath containing Kreb's Solution & buffer solution at 37°C & tension is added.

↓
Bath is bubbled by adding carbogen.

↓
Isometric contractile is measured by using polygraph.

↓
Spasmogen is added.

↓
Test drug is added (Isopropranolol 1 mg/kg)

↓
Obtain constant contractile add Spasmogen

↓
Add test drug

↓
Measure constant contractile obtain at maximum level.

Bronchospasmolytic activity in Guinea pig

Male Guinea pig
(200-300 g)

↓
Anesthetized with pentobarbitone.

Anesthetized is not much deep avoid Spontaneous
Respiratⁿ.

Jugular vein is cannulated by for test drug &
Spasmogen.

Carotid artery is measured for bp.

Trachea is cannulated by two way Trachea.
1) one trachea for transducer bp
2) one trachea for respiratⁿ.

Artificial aerosol is pumped at 190-200 mm in
1 min / stroke.

Measure & record the lung which is not taken
air.

Add Spasmogen (Histamine, HCl)

Contractile is produced & by adding Spasmogen
& test drug in 10-15 mints interval.

Broncho overactivity of Guinea pig:

Albino Guinea pig
(300-350g)

2) consists of Inhalation aerosol boxes A, B & C.

↓

Rat is placed in box A & treated with aerosol & the ultrasound nebulizer.

↓

Box B is passed way to Box C.

↓

In Box C produce 0.1% solution of HCl & histamine with ultrasound nebulizer.

↓

produce convulsions.

↓

Immediately remove animals from box.

5. Pharmacological Screening methods of antiulcer drugs

1) Pyrolic ligatin of rats.

2) Stress ulcer models

a) Restrain induced ulcers.

b) cold water immersion ulcers.

c) Stress & NSAIDs induced ulcers

d) Swimming, Stress ulcers.

3) Histamine induced gastric ulcers.

4) Acetic acid induced gastric ulcers.

5) Reserpine induced chronic gastric ulcers.

1) pyloric ligation of Rata

Wistar rats
(150-200 g)

fasting for
46 hrs but
given water

Anesthetized by
ether

Pylorus is lifted
carefully without
disturbing the
blood supply

1 inch abdominal
incision below
xiphoid process

Stomach is open
along greater
curvature

contents of stomach
are drained out by
graduated centrifuge

Measure the
Severity of
lesions

Acetic acid 0.01N NaCl
is used to centrifuge

$$U_I = U_N + U_S + U_p \times 10^{-1}$$

2) Stress ulcer models

a) Reserpine ^{Strain} induced ulcers

Albino rats
(150-200 g)

Fasted for 36
hours


Test compound administer
Orally

Keep Straining
in 24 hrs


Measure
gastric ulcers
by Straining animal.

Stomach is open &
dissected out

b) Cold-water immersion induced ulcers



c) Stress & NSAIDs induced ulcers



d) Swimming induced ulcers

Albino rats (170-200 g) → Fasted for 48 hrs but given water → Administer ~~test drug~~ & animals are forced to swim in deep tube 25°C for 5 hrs.

↓
Stomach is open along greater curvature ←

↓
After 5-7 hrs animals are strained.

↓
Lesions is measured as

- 0 - Lesions is absent
- 1 - Lesions \leq 1 mm
- 2 - Lesions \leq 1-2 mm
- 3 - Lesions \leq 2-4 mm
- 5 - Lesions \leq more than 4 mm

Histamine induced gastric ulcers

Wistar Guinea pig (200-250 g)

→ Fasting for 16 hrs →

Histamine injectⁿ IV →

To prevent Histamine toxicity ethazine is given before & after drug treatment

↓
Lesions is measured ←

↓
Stomach is open along greater curvature

Acetic acid induced gastric ulcers -

wistar rats (150-200 gms) → fasted for 24 hrs → Acetic acid (0.01) in 30 ml of injectⁿ is given at mucosal layer of stomach.

These are typically chronic ulcers regenerated with healing.

← Produce gastric ulcers by penetrating.

Reserpine induced chronic ulcers -

wistar rats (150-200 g) → provide Std diet → Before expt withdrawn liquid taken

1 mg/kg is given

↓
Given test drug Reserpine 2w.

↓
Stomach is open along greater curvature & Measure Severity of lesions.

2. Pharmacological Screening methods of antihypertensive agents and hepatoprotective drugs

In vivo

- 1) Two kidney 1 clip method in SD rats
- 2) One kidney 1 clip method in SD rats
- 3) Salt sensitive Dahl rats
- 4) Fructose induced hypertension in wistar rats
- 5) DOCA Salt rats
- 6) Tail cuff method.

Two kidney 1 clip method in Sprague Dawley rats

- The artery is constricted on only one side with the other artery left untouched.
- This results in sustained increase in BP.
- Initially, salt & water retention is more because the contact of other kidney being intact.
- In this situation the kidney resultant is angiotensin dependent.
- The increased angiotensin (II) is released from aldosterone from adrenal medulla.
- Salt & water retention is more
- This results in decrease renin production
- This is a volume dependent process (by extension)

one kidney 1 clip method in SD rats

Here one artery is constricted by only one side other is removed



Initially within a few hours bp increase.



There is no constriction of contra lateral kidney & no pressure diuresis & natriuresis.



Salt & H₂O retention is more




plasma renin usually normal.




Hypertension is volume dependent.


Salt Sensitive dahl rats




Fructose induced hypertension in wistar rats



DOCA Salt rate



Tail cuff method



→ After 5-6 weeks hypertension is attained → A inflatable cuff^{cuff} is attached at tail base.

↓
inflatable cuff is approximately reach 300 mm Hg.

↓
pressure of inflatable is slowly removed & pres bp is detected & record in polygraph.

↓
Administer test drug 2P for 3 times at in alternative days

↓
decreased bp

↓
Evaluate

Day 1: pre drug, 2 hrs post drug

Day 3: pre drug, 2 hrs post drug

Day 5: pre drug, 2 hrs post drug & 2 hrs post drug.

642 ✓


**Mid exam marks scored by students
are entered in the Mother register**


Pharmacology

I M.Ph / I Sem (2022-23)

Sub : Pharmacological & Toxicological Screening Methods - I (MPLU031) 262

| S.No | Register No | Name of the Student | Theory | | Average of Two | Practical Marks | Remarks |
|------|-------------|----------------------|--------|--------|----------------|-----------------|---------|
| | | | I mid | II mid | | | |
| 1 | 227NISO601 | BOYANAPALLI PRASANNA | 21 | 22 | 22 | N | |
| 2 | 227NISO602 | CHALAMALA RAMYANJALI | 19 | 20 | 20 | 0 | |
| 3 | 227NISO603 | SHATHI HAESA | 0 | 0 | 0 | P | |
| | | | | | | R | |
| | | | | | | A | |
| | | | | | | C | |
| | | | | | | T | |
| | | | | | | T | |
| | | | | | | C | |
| | | | | | | A | |
| | | | | | | L | |


 EXAMS-INCHARGE
VIJAYA INSTITUTE
 PHARMACEUTICAL SCIENCES FOR WOMEN
 ENIKEPADU, VIJAYAWADA 521 108


 PRINCIPAL
VIJAYA INSTITUTE OF
 PHARMACEUTICAL SCIENCES FOR WOMEN
 NIKEPADU, VIJAYAWADA 521 108

**Mid exam marks uploaded to
JNTUK University online portal**



JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY KAKINADA

FINAL PDF for M.Pharm I Semester Internal Marks

College: VIJAYA INSTITUTE OF PHARMACEUTICAL SCIENCES FOR WOMEN:7N

Date:19-05-2023

| HTNO | SUBJECT | MID_1 | MID_2 | SEMINAR | FINAL | SUB_TYPE |
|------------|----------|-------|-------|---------|-------|----------|
| 227N1S1601 | MPA101T | 25 | 25 | 0 | 25 | T |
| 227N1S1602 | MPA101T | 24 | 24 | 0 | 24 | T |
| 227N1S1603 | MPA101T | 24 | 25 | 0 | 25 | T |
| 227N1S1604 | MPA101T | 0 | 0 | 0 | 0 | T |
| 227N1S1605 | MPA101T | 25 | 25 | 0 | 25 | T |
| 227N1S1606 | MPA101T | 25 | 25 | 0 | 25 | T |
| 227N1S1607 | MPA101T | 24 | 25 | 0 | 25 | T |
| 227N1S1608 | MPA101T | 24 | 24 | 0 | 24 | T |
| 227N1S1601 | MPA102T | 25 | 25 | 0 | 25 | T |
| 227N1S1602 | MPA102T | 21 | 24 | 0 | 23 | T |
| 227N1S1603 | MPA102T | 23 | 25 | 0 | 24 | T |
| 227N1S1604 | MPA102T | 0 | 0 | 0 | 0 | T |
| 227N1S1605 | MPA102T | 22 | 24 | 0 | 23 | T |
| 227N1S1606 | MPA102T | 24 | 25 | 0 | 25 | T |
| 227N1S1607 | MPA102T | 24 | 24 | 0 | 24 | T |
| 227N1S1608 | MPA102T | 20 | 21 | 0 | 21 | T |
| 227N1S1601 | MPA103T | 23 | 25 | 0 | 24 | T |
| 227N1S1602 | MPA103T | 22 | 25 | 0 | 24 | T |
| 227N1S1603 | MPA103T | 23 | 25 | 0 | 24 | T |
| 227N1S1604 | MPA103T | 0 | 0 | 0 | 0 | T |
| 227N1S1605 | MPA103T | 22 | 25 | 0 | 24 | T |
| 227N1S1606 | MPA103T | 24 | 25 | 0 | 25 | T |
| 227N1S1607 | MPA103T | 25 | 25 | 0 | 25 | T |
| 227N1S1608 | MPA103T | 22 | 25 | 0 | 24 | T |
| 227N1S1601 | MPA104T | 25 | 25 | 0 | 25 | T |
| 227N1S1602 | MPA104T | 24 | 25 | 0 | 25 | T |
| 227N1S1603 | MPA104T | 25 | 25 | 0 | 25 | T |
| 227N1S1604 | MPA104T | 0 | 0 | 0 | 0 | T |
| 227N1S1605 | MPA104T | 25 | 25 | 0 | 25 | T |
| 227N1S1606 | MPA104T | 25 | 25 | 0 | 25 | T |
| 227N1S1607 | MPA104T | 25 | 25 | 0 | 25 | T |
| 227N1S1608 | MPA104T | 20 | 22 | 0 | 21 | T |
| 227N1S1601 | MPA105PA | 25 | 25 | 0 | 25 | L |
| 227N1S1602 | MPA105PA | 24 | 24 | 0 | 24 | L |
| 227N1S1603 | MPA105PA | 25 | 25 | 0 | 25 | L |
| 227N1S1604 | MPA105PA | 0 | 0 | 0 | 0 | L |
| 227N1S1605 | MPA105PA | 25 | 25 | 0 | 25 | L |
| 227N1S1606 | MPA105PA | 25 | 25 | 0 | 25 | L |
| 227N1S1607 | MPA105PA | 25 | 25 | 0 | 25 | L |
| 227N1S1608 | MPA105PA | 25 | 25 | 0 | 25 | L |
| 227N1S1601 | MPA105PB | 25 | 25 | 0 | 25 | L |
| 227N1S1602 | MPA105PB | 25 | 24 | 0 | 25 | L |

| HTNO | SUBJECT | MID_1 | MID_2 | SEMINAR | FINAL | SUB_TYPE |
|-------------|----------------|--------------|--------------|----------------|--------------|-----------------|
| 227N1S1603 | MPA105PB | 25 | 25 | 0 | 25 | L |
| 227N1S1604 | MPA105PB | 0 | 0 | 0 | 0 | L |
| 227N1S1605 | MPA105PB | 25 | 25 | 0 | 25 | L |
| 227N1S1606 | MPA105PB | 25 | 25 | 0 | 25 | L |
| 227N1S1607 | MPA105PB | 25 | 25 | 0 | 25 | L |
| 227N1S1608 | MPA105PB | 25 | 25 | 0 | 25 | L |
| 227N1S1601 | MPA106S | 0 | 0 | 98 | 98 | S |
| 227N1S1602 | MPA106S | 0 | 0 | 85 | 85 | S |
| 227N1S1603 | MPA106S | 0 | 0 | 98 | 98 | S |
| 227N1S1604 | MPA106S | 0 | 0 | 0 | 0 | S |
| 227N1S1605 | MPA106S | 0 | 0 | 97 | 97 | S |
| 227N1S1606 | MPA106S | 0 | 0 | 98 | 98 | S |
| 227N1S1607 | MPA106S | 0 | 0 | 85 | 85 | S |
| 227N1S1608 | MPA106S | 0 | 0 | 85 | 85 | S |
| 227N1S0301 | MPH101T | 25 | 25 | 0 | 25 | T |
| 227N1S0302 | MPH101T | 24 | 25 | 0 | 25 | T |
| 227N1S0303 | MPH101T | 24 | 24 | 0 | 24 | T |
| 227N1S0304 | MPH101T | 25 | 23 | 0 | 24 | T |
| 227N1S0305 | MPH101T | 24 | 24 | 0 | 24 | T |
| 227N1S0306 | MPH101T | 25 | 25 | 0 | 25 | T |
| 227N1S0307 | MPH101T | 24 | 25 | 0 | 25 | T |
| 227N1S0308 | MPH101T | 25 | 25 | 0 | 25 | T |
| 227N1S0309 | MPH101T | 24 | 25 | 0 | 25 | T |
| 227N1S0310 | MPH101T | 25 | 25 | 0 | 25 | T |
| 227N1S0311 | MPH101T | 23 | 22 | 0 | 23 | T |
| 227N1S0312 | MPH101T | 25 | 25 | 0 | 25 | T |
| 227N1S0313 | MPH101T | 0 | 0 | 0 | 0 | T |
| 227N1S0314 | MPH101T | 21 | 25 | 0 | 23 | T |
| 227N1S0301 | MPH102T | 25 | 24 | 0 | 25 | T |
| 227N1S0302 | MPH102T | 25 | 22 | 0 | 24 | T |
| 227N1S0303 | MPH102T | 24 | 23 | 0 | 24 | T |
| 227N1S0304 | MPH102T | 25 | 23 | 0 | 24 | T |
| 227N1S0305 | MPH102T | 24 | 24 | 0 | 24 | T |
| 227N1S0306 | MPH102T | 25 | 23 | 0 | 24 | T |
| 227N1S0307 | MPH102T | 21 | 22 | 0 | 22 | T |
| 227N1S0308 | MPH102T | 25 | 23 | 0 | 24 | T |
| 227N1S0309 | MPH102T | 22 | 23 | 0 | 23 | T |
| 227N1S0310 | MPH102T | 24 | 25 | 0 | 25 | T |
| 227N1S0311 | MPH102T | 18 | 23 | 0 | 21 | T |
| 227N1S0312 | MPH102T | 24 | 25 | 0 | 25 | T |
| 227N1S0313 | MPH102T | 0 | 0 | 0 | 0 | T |
| 227N1S0314 | MPH102T | 20 | 23 | 0 | 22 | T |
| 227N1S0301 | MPH103T | 24 | 25 | 0 | 25 | T |
| 227N1S0302 | MPH103T | 25 | 25 | 0 | 25 | T |
| 227N1S0303 | MPH103T | 25 | 25 | 0 | 25 | T |
| 227N1S0304 | MPH103T | 25 | 24 | 0 | 25 | T |
| 227N1S0305 | MPH103T | 25 | 25 | 0 | 25 | T |
| 227N1S0306 | MPH103T | 25 | 25 | 0 | 25 | T |
| 227N1S0307 | MPH103T | 25 | 25 | 0 | 25 | T |
| 227N1S0308 | MPH103T | 24 | 25 | 0 | 25 | T |

| HTNO | SUBJECT | MID_1 | MID_2 | SEMINAR | FINAL | SUB_TYPE |
|-------------|----------------|--------------|--------------|----------------|--------------|-----------------|
| 227N1S0309 | MPH103T | 24 | 25 | 0 | 25 | T |
| 227N1S0310 | MPH103T | 25 | 25 | 0 | 25 | T |
| 227N1S0311 | MPH103T | 24 | 22 | 0 | 23 | T |
| 227N1S0312 | MPH103T | 25 | 25 | 0 | 25 | T |
| 227N1S0313 | MPH103T | 0 | 0 | 0 | 0 | T |
| 227N1S0314 | MPH103T | 24 | 25 | 0 | 25 | T |
| 227N1S0301 | MPH104T | 22 | 25 | 0 | 24 | T |
| 227N1S0302 | MPH104T | 22 | 25 | 0 | 24 | T |
| 227N1S0303 | MPH104T | 22 | 25 | 0 | 24 | T |
| 227N1S0304 | MPH104T | 23 | 25 | 0 | 24 | T |
| 227N1S0305 | MPH104T | 24 | 25 | 0 | 25 | T |
| 227N1S0306 | MPH104T | 23 | 25 | 0 | 24 | T |
| 227N1S0307 | MPH104T | 19 | 25 | 0 | 22 | T |
| 227N1S0308 | MPH104T | 20 | 25 | 0 | 23 | T |
| 227N1S0309 | MPH104T | 21 | 25 | 0 | 23 | T |
| 227N1S0310 | MPH104T | 20 | 25 | 0 | 23 | T |
| 227N1S0311 | MPH104T | 15 | 23 | 0 | 19 | T |
| 227N1S0312 | MPH104T | 19 | 25 | 0 | 22 | T |
| 227N1S0313 | MPH104T | 0 | 0 | 0 | 0 | T |
| 227N1S0314 | MPH104T | 20 | 25 | 0 | 23 | T |
| 227N1S0301 | MPH105PA | 22 | 24 | 0 | 23 | L |
| 227N1S0302 | MPH105PA | 24 | 24 | 0 | 24 | L |
| 227N1S0303 | MPH105PA | 23 | 23 | 0 | 23 | L |
| 227N1S0304 | MPH105PA | 24 | 23 | 0 | 24 | L |
| 227N1S0305 | MPH105PA | 25 | 25 | 0 | 25 | L |
| 227N1S0306 | MPH105PA | 23 | 23 | 0 | 23 | L |
| 227N1S0307 | MPH105PA | 22 | 23 | 0 | 23 | L |
| 227N1S0308 | MPH105PA | 23 | 23 | 0 | 23 | L |
| 227N1S0309 | MPH105PA | 22 | 23 | 0 | 23 | L |
| 227N1S0310 | MPH105PA | 22 | 23 | 0 | 23 | L |
| 227N1S0311 | MPH105PA | 22 | 21 | 0 | 22 | L |
| 227N1S0312 | MPH105PA | 23 | 24 | 0 | 24 | L |
| 227N1S0313 | MPH105PA | 0 | 0 | 0 | 0 | L |
| 227N1S0314 | MPH105PA | 22 | 23 | 0 | 23 | L |
| 227N1S0301 | MPH105PB | 21 | 23 | 0 | 22 | L |
| 227N1S0302 | MPH105PB | 24 | 23 | 0 | 24 | L |
| 227N1S0303 | MPH105PB | 21 | 22 | 0 | 22 | L |
| 227N1S0304 | MPH105PB | 22 | 22 | 0 | 22 | L |
| 227N1S0305 | MPH105PB | 24 | 23 | 0 | 24 | L |
| 227N1S0306 | MPH105PB | 23 | 23 | 0 | 23 | L |
| 227N1S0307 | MPH105PB | 22 | 22 | 0 | 22 | L |
| 227N1S0308 | MPH105PB | 23 | 22 | 0 | 23 | L |
| 227N1S0309 | MPH105PB | 22 | 22 | 0 | 22 | L |
| 227N1S0310 | MPH105PB | 22 | 23 | 0 | 23 | L |
| 227N1S0311 | MPH105PB | 21 | 22 | 0 | 22 | L |
| 227N1S0312 | MPH105PB | 22 | 23 | 0 | 23 | L |
| 227N1S0313 | MPH105PB | 0 | 0 | 0 | 0 | L |
| 227N1S0314 | MPH105PB | 22 | 23 | 0 | 23 | L |
| 227N1S0301 | MPH106S | 0 | 0 | 85 | 85 | S |
| 227N1S0302 | MPH106S | 0 | 0 | 95 | 95 | S |

| HTNO | SUBJECT | MID_1 | MID_2 | SEMINAR | FINAL | SUB_TYPE |
|-------------|----------------|--------------|--------------|----------------|--------------|-----------------|
| 227N1S0303 | MPH106S | 0 | 0 | 80 | 80 | S |
| 227N1S0304 | MPH106S | 0 | 0 | 85 | 85 | S |
| 227N1S0305 | MPH106S | 0 | 0 | 98 | 98 | S |
| 227N1S0306 | MPH106S | 0 | 0 | 80 | 80 | S |
| 227N1S0307 | MPH106S | 0 | 0 | 85 | 85 | S |
| 227N1S0308 | MPH106S | 0 | 0 | 83 | 83 | S |
| 227N1S0309 | MPH106S | 0 | 0 | 95 | 95 | S |
| 227N1S0310 | MPH106S | 0 | 0 | 95 | 95 | S |
| 227N1S0311 | MPH106S | 0 | 0 | 80 | 80 | S |
| 227N1S0312 | MPH106S | 0 | 0 | 85 | 85 | S |
| 227N1S0313 | MPH106S | 0 | 0 | 0 | 0 | S |
| 227N1S0314 | MPH106S | 0 | 0 | 85 | 85 | S |
| 227N1S0601 | MPL101T | 25 | 25 | 0 | 25 | T |
| 227N1S0602 | MPL101T | 22 | 25 | 0 | 24 | T |
| 227N1S0603 | MPL101T | 0 | 0 | 0 | 0 | T |
| 227N1S0601 | MPL102T | 24 | 24 | 0 | 24 | T |
| 227N1S0602 | MPL102T | 22 | 24 | 0 | 23 | T |
| 227N1S0603 | MPL102T | 0 | 0 | 0 | 0 | T |
| 227N1S0601 | MPL103T | 21 | 22 | 0 | 22 | T |
| 227N1S0602 | MPL103T | 19 | 20 | 0 | 20 | T |
| 227N1S0603 | MPL103T | 0 | 0 | 0 | 0 | T |
| 227N1S0601 | MPL104T | 25 | 25 | 0 | 25 | T |
| 227N1S0602 | MPL104T | 23 | 24 | 0 | 24 | T |
| 227N1S0603 | MPL104T | 0 | 0 | 0 | 0 | T |
| 227N1S0601 | MPL105PA | 24 | 24 | 0 | 24 | L |
| 227N1S0602 | MPL105PA | 24 | 24 | 0 | 24 | L |
| 227N1S0603 | MPL105PA | 0 | 0 | 0 | 0 | L |
| 227N1S0601 | MPL105PB | 25 | 24 | 0 | 25 | L |
| 227N1S0602 | MPL105PB | 25 | 24 | 0 | 25 | L |
| 227N1S0603 | MPL105PB | 0 | 0 | 0 | 0 | L |
| 227N1S0601 | MPL106S | 0 | 0 | 98 | 98 | S |
| 227N1S0602 | MPL106S | 0 | 0 | 97 | 97 | S |
| 227N1S0603 | MPL106S | 0 | 0 | 0 | 0 | S |
| 227N1S1701 | MRA101T | 21 | 25 | 0 | 23 | T |
| 227N1S1702 | MRA101T | 22 | 25 | 0 | 24 | T |
| 227N1S1703 | MRA101T | 24 | 25 | 0 | 25 | T |
| 227N1S1704 | MRA101T | 24 | 25 | 0 | 25 | T |
| 227N1S1705 | MRA101T | 23 | 25 | 0 | 24 | T |
| 227N1S1706 | MRA101T | 25 | 25 | 0 | 25 | T |
| 227N1S1701 | MRA102T | 25 | 25 | 0 | 25 | T |
| 227N1S1702 | MRA102T | 25 | 25 | 0 | 25 | T |
| 227N1S1703 | MRA102T | 25 | 25 | 0 | 25 | T |
| 227N1S1704 | MRA102T | 25 | 25 | 0 | 25 | T |
| 227N1S1705 | MRA102T | 25 | 25 | 0 | 25 | T |
| 227N1S1706 | MRA102T | 25 | 25 | 0 | 25 | T |
| 227N1S1701 | MRA103T | 21 | 22 | 0 | 22 | T |
| 227N1S1702 | MRA103T | 19 | 22 | 0 | 21 | T |
| 227N1S1703 | MRA103T | 22 | 21 | 0 | 22 | T |
| 227N1S1704 | MRA103T | 24 | 23 | 0 | 24 | T |
| 227N1S1705 | MRA103T | 24 | 24 | 0 | 24 | T |

| HTNO | SUBJECT | MID_1 | MID_2 | SEMINAR | FINAL | SUB_TYPE |
|------------|----------|-------|-------|---------|-------|----------|
| 227N1S1706 | MRA103T | 23 | 24 | 0 | 24 | T |
| 227N1S1701 | MRA104T | 22 | 23 | 0 | 23 | T |
| 227N1S1702 | MRA104T | 23 | 22 | 0 | 23 | T |
| 227N1S1703 | MRA104T | 21 | 22 | 0 | 22 | T |
| 227N1S1704 | MRA104T | 25 | 25 | 0 | 25 | T |
| 227N1S1705 | MRA104T | 25 | 25 | 0 | 25 | T |
| 227N1S1706 | MRA104T | 25 | 25 | 0 | 25 | T |
| 227N1S1701 | MRA105PA | 21 | 21 | 0 | 21 | L |
| 227N1S1702 | MRA105PA | 22 | 21 | 0 | 22 | L |
| 227N1S1703 | MRA105PA | 22 | 21 | 0 | 22 | L |
| 227N1S1704 | MRA105PA | 24 | 24 | 0 | 24 | L |
| 227N1S1705 | MRA105PA | 24 | 24 | 0 | 24 | L |
| 227N1S1706 | MRA105PA | 23 | 24 | 0 | 24 | L |
| 227N1S1701 | MRA105PB | 24 | 24 | 0 | 24 | L |
| 227N1S1702 | MRA105PB | 24 | 24 | 0 | 24 | L |
| 227N1S1703 | MRA105PB | 25 | 24 | 0 | 25 | L |
| 227N1S1704 | MRA105PB | 24 | 24 | 0 | 24 | L |
| 227N1S1705 | MRA105PB | 24 | 24 | 0 | 24 | L |
| 227N1S1706 | MRA105PB | 25 | 24 | 0 | 25 | L |
| 227N1S1701 | MRA106S | 0 | 0 | 85 | 85 | S |
| 227N1S1702 | MRA106S | 0 | 0 | 80 | 80 | S |
| 227N1S1703 | MRA106S | 0 | 0 | 80 | 80 | S |
| 227N1S1704 | MRA106S | 0 | 0 | 98 | 98 | S |
| 227N1S1705 | MRA106S | 0 | 0 | 98 | 98 | S |
| 227N1S1706 | MRA106S | 0 | 0 | 95 | 95 | S |



Verified by: **PRINCIPAL**

Controller of Examinations

Date:19-05-2023